<HTML>
<HEAD>
   <TITLE>References</TITLE>
<META NAME="AUTHOR" CONTENT="William White">
</HEAD>
<BODY BGCOLOR="#FFFFFF">
<P><BR>
</P>

<P><BR>
</P>

<CENTER><A NAME="toc.17"></A></CENTER>

<H1><CENTER>17 &nbsp; References</CENTER></H1>

<P><BR>
</P>

<OL>
   <LI>White, William E.  The Dextromethorphan FAQ <B>1997</B> 
      (www.frognet.net/~dxm) <A NAME=r1></A></LI>
   
   <LI>Fleeger CA (ed). USAN and the USP Dictionary of Drug Names.
   USP Convention Inc. <B>1993</B> (Rockville) <A NAME=r2></A></LI>
   
   <LI>McEnvoy GK (ed). AHFS Drug Information. ASHP Inc. <B>1993</B>
   (Bethesda) <A NAME=r3></A></LI>
   
   <LI>Bem JL, Peck R. Dextromethorphan. An overview of safety
   issues. <I>Drug Saf</I>. <B>1992</B>;<I>7</I>:190-199.
   <A NAME=r4></A></LI>
   
   <LI>Murray S, Brewerton T. Abuse of over-the-counter
   dextromethorphan by teenagers. <I>South. Med. J.</I>.
   <B>1993</B>;<I>86</I>:1151-1153. <A NAME=r5></A></LI>
   
   <LI>Schadel M, Romach MK, Sellers EM. Mania and cough syrup
   &#91;letter&#93;. <I>J. Clin. Psychiatry</I>.
   <B>1993</B>;<I>54</I>:200. <A NAME=r6></A></LI>
   
   <LI>Craig DF. Psychosis with Vicks Formula 44-D abuse. <I>Can.
   Med. Assoc. J.</I>. <B>1992</B>;<I>146</I>:1199-1200.
   <A NAME=r7></A></LI>
   
   <LI>Jacobs MR, Fehr KO. Drugs and Drug Abuse. . <B>1987</B>
   (Toronto) <A NAME=r8></A></LI>
   
   <LI>Dukes, MNG (ed). Meyler's Side Effects of Drugs. Elsevier.
   <B>1992</B> (Amsterdam) <A NAME=r9></A></LI>
   
   <LI>Rammer L, Holmgren P, Sandler H. Fatal intoxication by
   dextromethorphan: a report on two cases. <I>Forensic Sci.
   Int.</I>. <B>1988</B>;<I>37</I>:233-236. <A NAME=r10></A></LI>
   
   <LI>Jacqz-Aigrain E, Cresteil T. Cytochrome P450-dependent
   metabolism of dextromethorphan: fetal and adult studies. <I>Dev.
   Pharmacol. &amp; Therapeutics</I>. <B>1992</B>;<I>18</I>:161-168.
   <A NAME=r11></A></LI>
   
   <LI>Kerry NL, Somogyi AA, et al. Primary and secondary oxidative
   metabolism of dextromethorphan. In vitro studies with female
   Sprague-Dawley and Dark agouti rat liver microsomes. <I>Biochem.
   Pharmacol.</I>. <B>1993</B>;<I>45</I>:833-839.
   <A NAME=r12></A></LI>
   
   <LI>Duche JC, Querol-Ferrer V, et al. Dextromethorphan O-
   demethylation and dextrorphan glucuronidation in a French
   population. <I>Int. J. Clin. Pharmacol., Therapy, &amp;
   Toxicology</I>. <B>1993</B>;<I>31</I>:392-398.
   <A NAME=r13></A></LI>
   
   <LI>Irshaid YM, al-Hadidi HF, Raweshdeh NM. Dextromethorphan O-
   demethylation polymorphism in Jordanians. <I>Eur. J. Clin.
   Pharmacol.</I>. <B>1993</B>;<I>45</I>:271-273.
   <A NAME=r14></A></LI>
   
   <LI>Freche JP, Dragacci S, et al. Development of an ELISA to study
   the polymorphism of dextromethorphan oxidation in a French
   population. <I>Eur. J. Clin. Pharmacol</I>.
   <B>1990</B>;<I>39</I>:481-485. <A NAME=r15></A></LI>
   
   <LI>Funck-Brentano C, Thomas G, et al. Polymorphism of
   dextromethorphan metabolism: relationships between phenotype,
   genotype, and response to the administration of encainide in
   humans. <I>J. Pharmacol. &amp; Exp. Therapeutics</I>.
   <B>1992</B>;<I>263</I>:780-786. <A NAME=r16></A></LI>
   
   <LI>Mura C, Panserat S, et al. DNA haplotype dependency of
   debrisoquine 4-hydroxylase (CYP2D6) expression among extensive
   metabolisers. <I>Human Gen.</I>. <B>1993</B>;<I>92</I>:367-372.
   <A NAME=r17></A></LI>
   
   <LI>Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and
   CYP3A-dependent metabolism of dextromethorphan in humans.
   <I>Pharmacogenetics</I>. <B>1993</B>;<I>3</I>:197-204.
   <A NAME=r18></A></LI>
   
   <LI>Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine
   hydroxylase) phenotype and genotype: inability of dextromethorphan
   metabolic ratio to discriminate reliably heterozygous and
   homozygous extensive metabolizers. <I>Pharmacogenetics</I>.
   <B>1991</B>;<I>1</I>:143-148. <A NAME=r19></A></LI>
   
   <LI>Meldrum BS. Excitatory amino acid receptors and disease.
   <I>Opin. Neurol. Neurosurg.</I>. <B>1992</B>;<I>5</I>:508-513.
   <A NAME=r20></A></LI>
   
   <LI>Radek RJ, Giardina WJ. The neuroprotective effects of
   dextromethorphan on guinea pig oxygen-derived hippocampal slices
   during hypoxia. <I>Neurosci. Lett.</I>.
   <B>1992</B>;<I>139</I>:191-193. <A NAME=r21></A></LI>
   
   <LI>Steinberg GK, Lo EH, et al. Dextromethorphan alters cerebral
   blood flow and protects against cerebral injury following focal
   ischemia. <I>Neurosci. Lett.</I>. <B>1991</B>;<I>133</I>:225-228.
   <A NAME=r22></A></LI>
   
   <LI>Steinberg GK, Kunis D, et al. Neuroprotection following focal
   cerebral ischaemia with the NMDA antagonist dextromethorphan, has
   a favourable dose response profile. <I>Neurological Res.</I>.
   <B>1993</B>;<I>15</I>:174-180. <A NAME=r23></A></LI>
   
   <LI>Panter SS, Faden AI. Pretreatment with NMDA antagonists limits
   release of excitatory amino acids following traumatic brain
   injury. <I>Neurosci. Lett.</I>. <B>1992</B>;<I>136</I>:165-168.
   <A NAME=r24></A></LI>
   
   <LI>Finnegan KT, Kerr JT, et al. Dextromethorphan protects against
   the neurotoxic effects of p-chloroamphetamine in rats. <I>Brain
   Res.</I>. <B>1991</B>;<I>558</I>:109-111. <A NAME=r25></A></LI>
   
   <LI>Henderson MG, Fuller RW. Dextromethorphan antagonizes the
   acute depletion of brain serotonin by p-chloroamphetamine and
   H75/12 in rats. <I>Brain Res.</I>. <B>1992</B>;<I>594</I>:323-326.
   <A NAME=r26></A></LI>
   
   <LI>Lancaster FE. Alcohol, nitric oxide, and neurotoxicity: is
   there a connection? - a review. <I>Alcohol Clin. Exp. Res.</I>.
   <B>1992</B>;<I>16</I>:539-541. <A NAME=r27></A></LI>
   
   <LI>Morgan PF. Is quinolinic acid an endogenous excitotoxin in
   alcohol withdrawal?. <I>Med. Hypotheses</I>.
   <B>1991</B>;<I>36</I>:118-121. <A NAME=r28></A></LI>
   
   <LI>Danysz W, Dyr W, et al. The involvement of NMDA receptors in
   acute and chronic effects of ethanol. <I>Alcohol Clin. Exp.
   Res</I>. <B>1992</B>;<I>16</I>:499-504. <A NAME=r29></A></LI>
   
   <LI>Morgan PF, Nadi NS, et al. Mapping rat brain structures
   activated during ethanol withdrawal: role of glutamate and NMDA
   receptors. <I>Eur. J. Pharmacol.</I>.
   <B>1992</B>;<I>225</I>:217-223. <A NAME=r30></A></LI>
   
   <LI>Heyes MP, Saito K, Markey SP. Human macrophages convert
   L-tryptophan into the neurotoxin quinolinic acid. <I>Biochem.
   J.</I>. <B>1992</B>;<I>283(pt 3)</I>:633-635.
   <A NAME=r31></A></LI>
   
   <LI>Heyes MP, Satio K, et al. Poliovirus induces
   indolamine-2,3-dioxygenase and quinolinic acid synthesis in
   macaque brain. <I>FASEB-J.</I>. <B>1992</B>;<I>6</I>:2977-2989.
   <A NAME=r32></A></LI>
   
   <LI>Loscher W, Honack D. Differences in anticonvulsant potency and
   adverse effects between dextromethorphan and dextrorphan in
   amygdala-kindled and non-kindled rats. <I>Eur. J. Pharmacol.</I>.
   <B>1993</B>;<I>238</I>:191-200. <A NAME=r33></A></LI>
   
   <LI>Schmitt B, Netzer R, et al. Drug refractory epilepsy in brain
   damage: effect of dextromethorphan on EEG in four patients. <I>J.
   Neurol., Neurosurg. &amp; Psychiatry</I>.
   <B>1994</B>;<I>57</I>:333-339. <A NAME=r34></A></LI>
   
   <LI>Koyuncuoglu H, Saydam B. The treatment of heroin addicts with
   dextromethorphan: a double-blind comparison of dextromethorphan
   with chlorpromazine. <I>Int. J. Clin. Pharmacol., Therapy, &amp;
   Toxicol.</I>. <B>1990</B>;<I>28</I>:147-152. <A NAME=r35></A></LI>
   
   <LI>Welch L, Sovner R. The treatment of a chronic organic mental
   disorder with dextromethorphan in a man with severe mental
   retardation. <I>Br. J. Psychiatry</I>.
   <B>1992</B>;<I>161</I>:118-120. <A NAME=r36></A></LI>
   
   <LI>Bonuccelli U, Del Dotto P, et al. Dextromethorphan and
   parkinsonism &#91;letter&#93;. <I>Lancet.</I>.
   <B>1992</B>;<I>340</I>:53. <A NAME=r37></A></LI>
   
   <LI>Chapman V, Dickenson AH. The combination of NMDA antagonism
   and morphine produces profound antinociception in the rat dorsal
   horn. <I>Brain Res.</I>. <B>1992</B>;<I>573</I>:321-323.
   <A NAME=r38></A></LI>
   
   <LI>Maneckjee R, Minna JD. Biologically active MK-801 and
   SKF-10,047 binding sites distinct from those in rat brain are
   expressed on human lung cancer cells. <I>Mol. Biol. Cell.</I>.
   <B>1992</B>;<I>3</I>:613-619. <A NAME=r39></A></LI>
   
   <LI>Otton SV, Wu D, et al. Inhibition by fluoxetine of cytochrome
   P450 2D6 activity. <I>Clin. Pharmacol. &amp; Therapeutics</I>.
   <B>1993</B>;<I>53</I>:401- 409. <A NAME=r40></A></LI>
   
   <LI>Achamallah NS. Visual hallucinations after combining
   fluoxetine and dextromethorphan &#91;letter&#93;. <I>Am. J.
   Psychiatry</I>. <B>1992</B>;<I>149</I>:1406. <A NAME=r41></A></LI>
   
   <LI>Kintz P, Mangin P. Toxicological findings in a death involving
   dextromethorphan and terfenadine. <I>Am. J. Forensic Med.
   Pathol.</I>. <B>1992</B>;<I>13</I>:351-352. <A NAME=r42></A></LI>
   
   <LI>Kamei J, Iwamoto Y, Misawa M, Kasuya Y. Effects of rimcazole,
   a specific antagonist of sigma sites, on the antitussive effects
   of non-narcotic antitussive drugs. <I>Eur. J. Pharmacol.</I>.
   <B>1993</B>;<I>242</I>:209-211. <A NAME=r43></A></LI>
   
   <LI>Szekely JI, Sharpe LG, Jaffe JH. Induction of
   phencyclidine-like behavior in rats by dextrorphan but not
   dextromethorphan. <I>Pharmacol. Biochem. Behav.</I>.
   <B>1991</B>;<I>40</I>:381-386. <A NAME=r44></A></LI>
   
   <LI>Klein M, Musacchi JM. High-affinity dextromethorphan and (+)-
   3-(3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat
   brain. Allosteric effects of ropizine. <I>J. Pharmacol. Exp.
   Ther.</I>. <B>1992</B>;<I>260</I>:990-999. <A NAME=r45></A></LI>
   
   <LI>Thompson KW, Westerlain CG. Dextromethorphan and its
   combination with phenytoin facilitate kindling. <I>Neurology</I>.
   <B>1993</B>;<I>43</I>:992-994. <A NAME=r46></A></LI>
   
   <LI>Simpson MD, Slater P, et al. Alterations in phencyclidine and
   sigma binding sites in schizophrenic brains. Effects of disease
   process and neuroleptic medication. <I>Schizophr. Res.</I>.
   <B>1991</B>;<I>6</I>:41- 48. <A NAME=r47></A></LI>
   
   <LI>Lang A, Vasar E, et al. The involvement of sigma and
   phencyclidine receptors in the action of antipsychotic drugs.
   <I>Pharmacol. Toxicol.</I>. <B>1992</B>;<I>71</I>:132-138.
   <A NAME=r48></A></LI>
   
   <LI>Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic
   cerebral cortices. <I>Neurochem. Res.</I>.
   <B>1992</B>;<I>17</I>:983-990. <A NAME=r49></A></LI>
   
   <LI>Debonnel G. Current hypotheses on sigma receptors and their
   physiological role: possible implications in psychiatry.
   &#91;Review&#93;. <I>J. Psychiatry &amp; Neurosci.</I>.
   <B>1993</B>;<I>18</I>:157-172. <A NAME=r50></A></LI>
   
   <LI>Micheletti G, Lannes B, et al. Chronic administration of NMDA
   antagonists induces D2 receptor synthesis in rat striatum.
   <I>Brain. Res. Mol. Brain Res.</I>. <B>1992</B>;<I>14</I>:362-368.
   <A NAME=r51></A></LI>
   
   <LI>Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in
   the brain-endocrine-immune axis. &#91;Review&#93;. <I>NIDA Res.
   Monograph Ser.</I>. <B>1993</B>;<I>133</I>:95-123.
   <A NAME=r52></A></LI>
   
   <LI>Huang X, Nichols DE. 5-HT2 receptor-mediated potentiation of
   dopamine synthesis and central serotonergic deficits. <I>Eur. J.
   Pharmacol.</I>. <B>1993</B>;<I>238</I>:291-296.
   <A NAME=r53></A></LI>
   
   <LI>Khanna JM, Shah G, Weiner J, et al. Effect of NMDA receptor
   antagonists on rapid tolerance to ethanol. <I>Eur. J.
   Pharmacol.</I>. <B>1993</B>;<I>230</I>:23-31.
   <A NAME=r54></A></LI>
   
   <LI>Schneider SM, Michelson EA, et al. Dextromethorphan poisoning
   reversed by naloxone. &#91;Review&#93;. <I>Am. J. Emerg. Med.</I>.
   <B>1991</B>;<I>9</I>:237- 238. <A NAME=r55></A></LI>
   
   <LI>Kamei J, Iwamoto Y, et al. Involvement of
   haloperidol-sensitive sigma-sites in antitussive effects. <I>Eur.
   J. Pharmacol.</I>. <B>1992</B>;<I>224</I>:39-43.
   <A NAME=r56></A></LI>
   
   <LI>Kamei J, Mori T, et al. Serotonin release in nucleus of the
   solitary tract and its modulation by antitussive drugs. <I>Res.
   Commun. Chem. Pathol. Pharmacol.</I>.
   <B>1992</B>;<I>76</I>:371-374. <A NAME=r57></A></LI>
   
   <LI>Kamei J, Mori T, et al. Effects of 8-hydroxy-2-(di-n-
   propylamino)tetralin, a selective agonist of 5-HT1A receptors, on
   the cough reflex in rats. <I>Eur. J. Pharmacol.</I>.
   <B>1991</B>;<I>203</I>:253-258. <A NAME=r58></A></LI>
   
   <LI>Zhou GZ, Musacchio JM. Computer-assisted modeling of multiple
   dextromethorphan and sigma binding sites in guinea pig brain.
   <I>Eur. J. Pharmacol.</I>. <B>1991</B>;<I>206</I>:261-269.
   <A NAME=r59></A></LI>
   
   <LI>Netzer R, Pflimlin P, Trube G. Dextromethorphan blocks N-
   methyl-D-aspartate-induced currents and voltage-operated inward
   currents in cultured cortical neurons. <I>Eur. J. Pharmacol.</I>.
   <B>1993</B>;<I>238</I>:209-216. <A NAME=r60></A></LI>
   
   <LI>Canoll PD, Smith PR, Musacchio JM. Ropizine concurrently
   enhances and inhibits &#91;3H&#93;dextromethorphan binding to
   different structures of the guinea pig brain: autoradiographic
   evidence for multiple binding sites. <I>Life Sci.</I>.
   <B>1990</B>;<I>46</I>:PL9-16. <A NAME=r61></A></LI>
   
   <LI>Weight FF, Aguayo LG, et al. GABA- and glutamate-gated ion
   channels as molecular sites of alcohol and anesthetic action.
   <I>Adv. Biochem. Psychopharmacol.</I>.
   <B>1992</B>;<I>47</I>:335-347. <A NAME=r62></A></LI>
   
   <LI>Sanna E, Serra M, et al. GABAA and NMDA receptor function
   during chronic administration of ethanol. <I>Adv. Biochem.
   Psychopharmacol.</I>. <B>1992</B>;<I>47</I>:317-324.
   <A NAME=r63></A></LI>
   
   <LI>Bubser M, Keseberg U, Notz PK, Schmidt WJ. Differential
   behavioural and neurochemical effects of competitive and non
   competitive NMDA receptor antagonists in rats. <I>Eur. J.
   Pharmacol.</I>. <B>1992</B>;<I>229</I>:75-82.
   <A NAME=r64></A></LI>
   
   <LI>Oye I, Paulsen O, et al. Effects of ketamine on sensory
   perception: evidence for a role of N-methyl-D-aspartate receptors.
   <I>Pharmacol. Exp. Ther.</I>. <B>1992</B>;<I>260</I>:1209-1213.
   <A NAME=r65></A></LI>
   
   <LI>Miller CL, Bickford PC, et al. Phencyclidine and auditory
   sensory gating in the hippocampus of the rat.
   <I>Neuropharmacology</I>. <B>1992</B>;<I>31</I>:1041-1048.
   <A NAME=r66></A></LI>
   
   <LI>Mayer ML, Benveniste M, et al. Pharmacologic properties of
   NMDA receptors. <I>Ann. N.Y. Acad. Sci.</I>.
   <B>1992</B>;<I>648</I>:194-204. <A NAME=r67></A></LI>
   
   <LI>Gasic GP, Heinemann S. Receptors coupled to ionic channels:
   the glutamate receptor family. <I>Curr. Opin. Neurobiol.</I>.
   <B>1991</B>;<I>1</I>:20- 26. <A NAME=r68></A></LI>
   
   <LI>Bortolotto ZA, Collingridge GL. Activation of glutamate
   metabotropic receptors induces long-term potentiation. <I>Eur. J.
   Pharmacol.</I>. <B>1992</B>;<I>214</I>:297-298.
   <A NAME=r69></A></LI>
   
   <LI>Walker JM, Bowen WD, et al. A comparison of (-)-
   deoxybenzomorphans devoid of opiate activity with their
   dextrorotary phenolic counterparts suggests role of sigma-2
   receptors in motor function. <I>Eur. J. Pharmacol.</I>.
   <B>1993</B>;<I>231</I>:61-68. <A NAME=r70></A></LI>
   
   <LI>Akunne HC, Johannessen JN, et al. MPTP lesions of the
   nigrostriatal dopaminergic projection decrease
   &#91;3H&#93;1-&#91;1-(2- thienyl)cyclohexyl)piperidine binding to
   PCP site 2: further evidence that PCP site 2 is associated with
   the biogenic amine reuptake complex. <I>Neurochem. Res.</I>.
   <B>1992</B>;<I>17</I>:261-264. <A NAME=r71></A></LI>
   
   <LI>Rogers C, Lemaire S. Characterization of
   &#91;3H&#93;desmethylimipramine binding in bovine adrenal medulla:
   interactions with sigma- and (or) phencyclidine-receptor ligands.
   <I>Can. J. Physiol. Pharmacol.</I>.
   <B>1992</B>;<I>70</I>:1508-1514. <A NAME=r72></A></LI>
   
   <LI>Izenwasser S, Newman AH, Katz JL. Cocaine and several sigma
   receptor ligands inhibit dopamine uptake in rat caudate-putamen.
   <I>Eur. J. Pharmacol.</I>. <B>1993</B>;<I>243</I>:201-205.
   <A NAME=r73></A></LI>
   
   <LI>Witkin JM, Terry P, et al. Effects of the selective sigma
   receptor ligand, 6-&#91;6-(4-hydroxypiperidinyl)hexyloxyl-3-
   methylflavone (NPC 16377), on behavioral and toxic effects of
   cocaine. <I>J. Pharmacol. &amp; Exp. Therapeutics</I>.
   <B>1993</B>;<I>266</I>:473-482. <A NAME=r74></A></LI>
   
   <LI>Shirayama Y, Nishikawa T, Umino A, Takahashi K.
   p-Chlorophenylalanine-reversible reduction of sigma binding sites
   by chronic imipramine treatment in rat brain. <I>Eur. J.
   Pharmacol.</I>. <B>1993</B>;<I>237</I>:117-126.
   <A NAME=r75></A></LI>
   
   <LI>Massamiri T, Duckles SP. Interactions of sigma and
   phencyclidine receptor ligands with the norepinephrine uptake
   carrier in both rat brain and rat tail artery. <I>J. Pharmacol.
   Exp. Ther.</I>. <B>1991</B>;<I>256</I>:519-524.
   <A NAME=r76></A></LI>
   
   <LI>Rao TS, Cler JA, et al. Neurochemical characterization of
   dopaminergic effects of opipramol, a potent sigma receptor ligand,
   in vivo. <I>Neuropharmacology</I>. <B>1991</B>;<I>4</I>:95-102.
   <A NAME=r77></A></LI>
   
   <LI>Gorski JC, Jones DR, et al. Characterization of
   dextromethorphan N-demethylation by human liver microsomes.
   Contribution of the cytochrome P450 3A (CYP3A) subfamily.
   <I>Biochem. Pharmacol.</I>. <B>1994</B>;<I>48</I>:173-182.
   <A NAME=r78></A></LI>
   
   <LI>Conner MA, Chavkin C. Ionic zinc may function as an endogenous
   ligand for the haloperidol-sensitive sigma 2 receptor in rat
   brain. <I>Mol. Pharmacol.</I>. <B>1992</B>;<I>42</I>:471-479.
   <A NAME=r79></A></LI>
   
   <LI>Jeanjean AP, Mestre M, Maloteaux JM, et al. Is the sigma-2
   receptor in rat brain related to the K+ channel of class III
   antiarrhythmic drugs?. <I>Eur J. Pharmacol.</I>.
   <B>1993</B>;<I>241</I>:111-116. <A NAME=r80></A></LI>
   
   <LI>Itzhak Y. Repeated methamphetamine-treatment alters brain
   sigma receptors. <I>Eur. J. Pharmacol</I>.
   <B>1993</B>;<I>230</I>:243-244. <A NAME=r81></A></LI>
   
   <LI>Mash DC, Zabetian CF. Sigma receptors are associated with
   cortical limbic areas in the primate brain. <I>Synapse</I>.
   <B>1992</B>;<I>12</I>:195- 205. <A NAME=r82></A></LI>
   
   <LI>Roman FJ, Martin B, Junien JL. In vivo interaction of
   neuropeptide Y and peptide YY with sigma receptor sites in the
   mouse brain. <I>Eur. J. Pharmacol.</I>.
   <B>1993</B>;<I>242</I>:305-307. <A NAME=r83></A></LI>
   
   <LI>Karbon EW, Enna SJ. Pharmacological characterization of sigma
   binding sites in guinea pig brain membranes. <I>Adv. Exp. Med.
   Biol.</I>. <B>1991</B>;<I>287</I>:51-59. <A NAME=r84></A></LI>
   
   <LI>Klein M, Canoll PD, Musacchio JM. SKF 525-A and cytochrome
   P-450 ligands inhibit with high affinity the binding of
   &#91;3H&#93;dextromethorphan and sigma ligands to guinea pig
   brain. <I>Life Sci.</I>. <B>1991</B>;<I>48</I>:543-550.
   <A NAME=r85></A></LI>
   
   <LI>Larson AA, Sun X. Regulation of sigma activity by amine-
   terminus of substance P in the mouse spinal cord: involvement of
   phencyclidine (PCP) sites not linked to N-methyl-D-aspartate
   (NMDA) activity. <I>Neuropharmacology</I>.
   <B>1993</B>;<I>32</I>:909-917. <A NAME=r86></A></LI>
   
   <LI>Su TP. Deliniating biochemical and functional properties of
   sigma receptors: emerging concepts. &#91;Review&#93;. <I>Crit.
   Rev. in Neurobiol.</I>. <B>1993</B>;<I>7</I>:187-203.
   <A NAME=r87></A></LI>
   
   <LI>Beaton JA, Stemsrud K, Monaghan DT. Identification of a novel
   N-methyl-D-aspartate receptor population in the rat medial
   thalamus. <I>J. Neurochem.</I>. <B>1992</B>;<I>59</I>:754-757.
   <A NAME=r88></A></LI>
   
   <LI>Keller EA, Borghese CM, et al. The learning capacity of high
   or low performance rats is related to the hippocampus NMDA
   receptors. <I>Brain Res.</I>. <B>1992</B>;<I>576</I>:162-164.
   <A NAME=r89></A></LI>
   
   <LI>Loscher W, Annies R, Honack D. Comparison of competitive and
   uncompetitive NMDA receptor antagonists with regard to
   monoaminergic neuronal activity and behavioural effects in rats.
   <I>Eur. J. Pharmacol.</I>. <B>1993</B>;<I>242</I>:263-274.
   <A NAME=r90></A></LI>
   
   <LI>Loscher W, Honack D. Effects of the novel 5-HT1A receptor
   antagonist, (+)-WAY 100135, on the stereotyped behaviour induced
   by NMDA receptor antagonist dizocilpine in rats. <I>Eur. J.
   Pharmacol.</I>. <B>1993</B>;<I>242</I>:99-104.
   <A NAME=r91></A></LI>
   
   <LI>Brent PJ, Chahl LA, Cantarella PA, Kavanagh C. The kappa-
   opioid receptor agonist UH50,488H induces acute physical
   dependence in guinea-pigs. <I>Eur. J. Pharmacol.</I>.
   <B>1993</B>;<I>241</I>:149-156. <A NAME=r92></A></LI>
   
   <LI>Grynne BH, Holmen AT, Maurset A. Evidence for distinct
   phencyclidine and SKF10047 receptors following detergent treatment
   of rat brain membranes. <I>Pharmacol. Toxicol.</I>.
   <B>1992</B>;<I>70</I>:25-30. <A NAME=r93></A></LI>
   
   <LI>Muraki A, Komaya T, et al. MK-801, a non-competative
   antagonist of NMDA receptor, prevents methamphetamine-induced
   decrease of striatal dopamine uptake sites in the rat striatum.
   <I>Neurosci. Lett</I>. <B>1992</B>;<I>136</I>:39-42.
   <A NAME=r94></A></LI>
   
   <LI>Simpson MD, Slater P, et al. Regionally selective deficits in
   uptake sites for glutamate and gamma-aminobutyric acid in the
   basal ganglia in schizophrenia. <I>Psychiatry Res.</I>.
   <B>1992</B>;<I>42</I>:273-282. <A NAME=r95></A></LI>
   
   <LI>Shinn AF (ed). Evaluations of Drug Interactions. Macmillan.
   <B>1988</B> (NY) <A NAME=r96></A></LI>
   
   <LI>Newman AH, Bevan K, et al. Synthesis and Evaluation of
   3-Substituted 17-Methylmorphinan Analogs as Potential
   Anticonvulsant Agents. <I>J. Med. Chem.</I>.
   <B>1992</B>;<I>35</I>:4135-4142. <A NAME=r97></A></LI>
   
   <LI>Su, Tsung-Ping. Pharmacologic Characterizations of Sigma
   Receptors. <I>Sigma, PCP, and NMDA Receptors</I>. <B>1993</B>:NIDA
   Research Monograph 133. <A NAME=r98></A></LI>
   
   <LI>Quirion R, DiMaggio DA, et al. Evidence for an endogenous
   peptide ligand for the phencyclidine receptor. <I>Peptides</I>.
   <B>1984</B>;<I>5</I>:967-973. <A NAME=r99></A></LI>
   
   <LI>DiMaggio DA, Contreras PC, et al. Biological and chemical
   characterization of the endopsychosins: Distinct ligands for PCP
   and sigma sites. Sigma and Phencyclidine-Like Compounds as
   Molecular Probes in Biology. NPP Books. <B>1988</B> (Ann Arbor)
   <A NAME=r100></A></LI>
   
   <LI>Rothman SM, Olney JW. Excitotoxicity and the NMDA Receptor -
   still lethal after eight years. <I>Trends in Neurosci.</I>.
   <B>1995</B>;<I>18</I>:57-58. <A NAME=r101></A></LI>
   
   <LI>Vilner et al. Sigma receptor mediated morphologic and
   cytotoxic effects. <I>J. Neurosci.</I>.
   <B>1995</B>;<I>15(1)</I>:118-134. <A NAME=r102></A></LI>
   
   <LI>Yamada M, Nishigami T, et al. Relationship between sigma-like
   site and progesterone-binding site of adult male rat liver
   microsomes. <I>Hepatology</I>. <B>1994</B>;<I>Nov</I>:1271-1280.
   <A NAME=r103></A></LI>
   
   <LI>N/A. Cocaine-sensitive sigma receptor and its interaction with
   steroid hormones in the human placental syncytiotrophoblast and in
   choriocarcinoma cells. <I>Endocrinology</I>.
   <B>1995</B>;<I>136(3)</I>:924-923. <A NAME=r104></A></LI>
   
   <LI>N/A. A role of sigma receptors on hypoxia/hypoglycemia-induced
   decrease in CA1 presynaptic fiber spikes in rat hippocampal
   slices. <I>Brain Res.</I>. <B>1995</B>;<I>670(2)</I>:337-341.
   <A NAME=r105></A></LI>
   
   <LI>N/A. Sigma-1 and sigma-2 receptors are expressed in a wide
   variety of human and rodent tumor cell lines. <I>Cancer Res.</I>.
   <B>1995</B>;<I>55(2)</I>:408-413. <A NAME=r106></A></LI>
   
   <LI>N/A. The sigma-selective ligand NE-100 attenuates the effect
   of phencyclidine in a rat diving model. <I>Gen. Pharmacol.</I>.
   <B>1995</B>;<I>26(1)</I>:177-182. <A NAME=r107></A></LI>
   
   <LI>N/A. Effect of NE-100, a novel sigma receptor ligand, on
   phencyclidine-induced cognitive dysfunction. <I>Eur. J.
   Pharmacol</I>. <B>1994</B>;<I>263(1 part 2)</I>:9-15.
   <A NAME=r108></A></LI>
   
   <LI>N/A. Sigma receptor mediated neuroprotection against glutamate
   toxicity in primary rat neuronal cultures. <I>Brain Res.</I>.
   <B>1995</B>;<I>671(1)</I>:45-53. <A NAME=r109></A></LI>
   
   <LI>N/A. Altered N-methyl-D-aspartate (NMDA) activity in the mouse
   spinal cord following morphine is mediated by sigma activity.
   <I>Brain Res.</I>. <B>1995</B>;<I>672(1 part 2)</I>:83-88.
   <A NAME=r110></A></LI>
   
   <LI>N/A. The role of NMDA and sigma systems in the behavioral
   effects of phencyclidine in preweanling rats.
   <I>Neurotoxicol.</I>. <B>1994</B>;<I>15(1)</I>:191-200.
   <A NAME=r111></A></LI>
   
   <LI>N/A. Substance P analogs displace sigma binding differentially
   in the brain and spinal cord of the adult mouse. <I>Metabol. Brain
   Diseases</I>. <B>1994</B>;<I>9(3)</I>:249-255.
   <A NAME=r112></A></LI>
   
   <LI>N/A. Sigma-receptor regulation of &#91;3H&#93;arachidonic acid
   release from rat neonatal cerebellar granule cells in culture.
   <I>J. Neurochem</I>. <B>1994</B>;<I>63(4)</I>:1311-1318.
   <A NAME=r113></A></LI>
   
   <LI>N/A. Regulation of &#91;3H&#93;dopamine release from rat
   striatal slices by sigma receptor ligands. <I>J. Pharmacol &amp;
   Exp. Therapeutics</I>. <B>1994</B>;<I>271(1)</I>:212-220.
   <A NAME=r114></A></LI>
   
   <LI>N/A. Conformational analysis, pharmacophore identification,
   and comparative molecular field analysis of ligands for the
   neuromodulatory sigma 3 receptor. <I>J. Medicinal Chem.</I>.
   <B>1994</B>;<I>37(24)</I>:4109-4117. <A NAME=r115></A></LI>
   
   <LI>N/A. Discriminative stimulus effects of dextromethorphan in
   rats. <I>Psychopharmacol.</I>. <B>1994</B>;<I>116(3)</I>:249-254.
   <A NAME=r116></A></LI>
   
   <LI>Behavioral evidence for a modulating role of sigma ligands in
   memory process. I. Attenuation of dizocilpine (MK-801)-induced
   amnesia. <I>Brain Res.</I>. <B>1994</B>;<I>647(1)</I>:44-56.
   <A NAME=r117></A></LI>
   
   <LI>Behavioral evidence for a modulating role of sigma ligands in
   memory process. II. Reversion of carbon monoxide-induced amnesia.
   <I>Brain Res</I>. <B>1994</B>;<I>647(1)</I>:57-64.
   <A NAME=r118></A></LI>
   
   <LI>Chein CC, Pasternak GW. Functional antagonism of morphine
   analgesia by (+)-pentazocine: evidence for an anti-opioid sigma 1
   system. <I>Eur. J. Pharmacol</I>. <B>1993</B>;<I>250(1)</I>:R7-R8.
   <A NAME=r119></A></LI>
   
   <LI>Jansen KL, Faull RL, et al. Loss of sigma binding sites in the
   CA1 area of the anterior hippocampus in Alzheimer's disease
   correlates with CA1 pyramidal cell loss. <I>Brain Res.</I><B><I>
   </I></B>. <B>1993</B>;<I>632(2)</I>:299-302.
   <A NAME=r120></A></LI>
   
   <LI>N/A. Pharmacological characteristics of hyperambulation
   induced by the sigma ligand (+)-3-PPP in rats. <I>Japanese J.
   Pharmacol.</I>. <B>1994</B>;<I>65(1)</I>:1-7.
   <A NAME=r121></A></LI>
   
   <LI>N/A. 4-Methoxyphenyl
   4-(3,4,5-trimethoxybenzyl)-1-piperazineacetate monofumarate
   monohydrate (KB-5492), a new anti-ulcer agent with a selective
   affinity for the sigma receptor, prevents cysteamine-induced
   duodenal ulcers in rats by a mechanism different from that of
   cimetidine. <I>Japanese J. Pharmacol</I>.
   <B>1994</B>;<I>64(3)</I>:221-224. <A NAME=r122></A></LI>
   
   <LI>N/A. Novel (4-phenylpiperidinyl)- and
   (4-phenylpiperazinyl)alkyl-spaced esters of
   1-phenylcyclopentanecarboxylic acids as potent sigma-selective
   compounds. <I>J. Medicinal Chem</I>.
   <B>1994</B>;<I>37(13)</I>:1964-1970. <A NAME=r123></A></LI>
   
   <LI>N/A. Rat liver and kidney contain high densities of sigma 1
   and sigma 2 receptors: characterization by ligand binding and
   photoaffinity labeling. <I>Eur J. Pharmacol</I>.
   <B>1994</B>;<I>268(1)</I>:9-18. <A NAME=r124></A></LI>
   
   <LI>N/A. Sigma receptor ligands modulate contractility, Ca2+
   influx and beating rate in cultured cardiac myocytes. <I>J.
   Pharmacol &amp; Exp. Therapeutics</I>.
   <B>1994</B>;<I>269(3)</I>:1300-1309. <A NAME=r125></A></LI>
   
   <LI>N/A. Modulation of the PCP/NMDA receptor complex and sigma
   binding sites by psychostimulants. <I>Neurotoxicol. &amp;
   Teratol.</I>. <B>1994</B>;<I>16(4)</I>:363-368.
   <A NAME=r126></A></LI>
   
   <LI>N/A. PCP Site 2: a high affinity MK-801-insensitive
   phencyclidine binding site. <I>Neurotoxicol &amp; Teratol</I>.
   <B>1994</B>;<I>16(4)</I>:343-53. <A NAME=r127></A></LI>
   
   <LI>N/A. Novel 1-phenylcycloalkanecarboxylic acid derivatives are
   potent and selective sigma 1 ligands. <I>J Medicinal Chem</I>.
   <B>1994;</B>;<I>37(15)</I>:2285-2291. <A NAME=r128></A></LI>
   
   <LI>N/A. SKF-10,047 reverses stress-induced motor suppression:
   interaction with dopaminergic system. <I>Eur J Pharmacol</I>.
   <B>1994</B>;<I>260(1)</I>:39-46. <A NAME=r129></A></LI>
   
   <LI>N/A. Sigma-1 and sigma-2 sites in rat brain: comparison of
   regional, ontogenetic, and subcellular patterns. <I>Synapse</I>.
   <B>1994</B>;<I>17(3)</I>:182-189. <A NAME=r130></A></LI>
   
   <LI>N/A. Ameliorating effects of sigma receptor ligands on the
   impairment of passive avoidance tasks in mice: involvement in the
   central acetylcholinergic system. <I>Eur J Pharmacol</I>.
   <B>1994</B>;<I>261(1-2)</I>:43-51. <A NAME=r131></A></LI>
   
   <LI>N/A. Low dose of 1,3-di(2-tolyl)guanidine (DTG) attenuates
   MK-801 induced spatial working memory impairment in mice.
   <I>Psychopharmacol</I>. <B>1994</B>;<I>114(3)</I>:520-522.
   <A NAME=r132></A></LI>
   
   <LI>N/A. Massive dextromethorphan ingestion and abuse. <I>Am J.
   Emerg. Med</I>. <B>1995</B>;<I>13(2)</I>:174-176.
   <A NAME=r133></A></LI>
   
   <LI>N/A. The combination of tizanidine markedly improves the
   treatment with dextromethorphan of heroin addicted outpatients.
   <I>Int. J Clin Pharmacol &amp; Therapeutics</I>.
   <B>1995</B>;<I>33(1)</I>:13-19. <A NAME=r134></A></LI>
   
   <LI>N/A. Neuroprotection by N-methyl-D-aspartate antagonists in
   focal cerebral ischemia is dependent on continued maintenance
   dosing. <I>Neuroscience</I>. <B>1995;</B>;<I>64(1)</I>:99-107.
   <A NAME=r135></A></LI>
   
   <LI>N&auml;kki R, Koistinaho J, et al. Cerebellar toxicity of
   phencyclidine. <I>J. Neurosci.</I>.
   <B>1995</B>;<I>15(3)</I>:2097-2108. <A NAME=r136></A></LI>
   
   <LI>Hinsberger A, Sharma V, Mazimian D. Cognitive deterioration
   from long-term abuse of dextromethorphan: a case report. <I>J.
   Psychiatry &amp; Neurosci.</I>. <B>1994</B>;<I>19(5)</I>:375-377.
   <A NAME=r137></A></LI>
   
   <LI>Hofstadter DR. G&ouml;del, Escher, Bach: an eternal golden
   braid. Basic Books;. <B>1979</B> (New York) <A NAME=r138></A></LI>
   
   <LI>Itzhak Y (editor). Sigma receptors. Academic Press;.
   <B>1994</B> (San Diego) <A NAME=r139></A></LI>
   
   <LI>McElwee NE, Veltri JC. Intentional abuse of dextromethorphan
   (DM) products: 1985 to 1988 statewide data. <I>Vet. Hum.
   Toxicol.</I>. <B>1990</B>;<I>32</I>:355. <A NAME=r140></A></LI>
   
   <LI>Fleming PM. Dependence on dextromethorphan hydrobromide.
   <I>BMJ</I>. <B>1986</B>;<I>293</I>:597. <A NAME=r141></A></LI>
   
   <LI>Helfer J, Kim OM. Psychoactive abuse potential of Robitussin
   DM. <I>Am. J. Psychiatry</I>. <B>1990</B>;<I>147</I>:5.
   <A NAME=r142></A></LI>
   
   <LI>Fisher R, Cysyk B, et al. Dextromethorphan for treatment of
   complex partial seizures. <I>Neurology</I>.
   <B>1990</B>;<I>40</I>:547-549. <A NAME=r143></A></LI>
   
   <LI>Delvin KM, Hall AH, Smolinske SC, et al. Toxicity from
   long-lasting dextromethorphan preparations. <I>Vet. Hum.
   Toxicol.</I>. <B>1985</B>;<I>28</I>:296. <A NAME=r144></A></LI>
   
   <LI>Ng YY, Lin WL, et al. Spurious hyperchloremia and decreased
   anion gap in a patient with dextromethorphan bromide. <I>Am J
   Nephrol</I>. <B>1992</B>;<I>12</I>:268-70. <A NAME=r145></A></LI>
   
   <LI>Baldwin SJ, Bloomer JC, et al. Ketoconazole and
   sulphaphenazole as the respective selective inhibitors of P4503A
   and 2C9. <I>Xenobiotica</I>. <B>1995</B>;<I>25(3)</I>:261-70.
   <A NAME=r146></A></LI>
   
   <LI>Yun CH, Jeong HG, et al. Non-specific inhibition of cytochrome
   P450 activities by chlorphyllin in human and rat liver microsomes.
   <I>Carcinogenesis</I>. <B>1995</B>;<I>16(6)</I>:1437-40.
   <A NAME=r147></A></LI>
   
   <LI>Gram LF, Guentert TW, et al. Moclobemide, a substrate of
   CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel
   study. <I>Clin Pharmacol &amp; Ther</I>.
   <B>1995</B>;<I>57(6)</I>:670-7. <A NAME=r148></A></LI>
   
   <LI>Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors.
   Evaluation of specificities in the in vitro metabolism of
   therapeutic agents by human liver microsomes. <I>Drug Metabolism
   &amp; Disposition</I>. <B>1995</B>;<I>23(1)</I>:154-8.
   <A NAME=r149></A></LI>
   
   <LI>Kimonen T, Juvonen RO, et al. The inhibition of CYP enzymes in
   mouse and human liver by pilocarpine. <I>Br J Pharmacol</I>.
   <B>1995</B>;<I>114(4)</I>:832-6. <A NAME=r150></A></LI>
   
   <LI>Hiratsuka A, Chu TY, et al. Inactivation of constitutive
   hepatic cytochromes P450 by phencyclidine in the rat. <I>Drug
   Metabolism &amp; Disposition</I>. <B>1995</B>;<I>23(2)</I>:201-6.
   <A NAME=r151></A></LI>
   
   <LI>Hiroi T, Ohishi N, et al. Mepyramine, a histamine H1 receptor
   antagonist, inhibits the metabolic activity of rat and human P450
   2D forms. <I>J Pharmacol &amp; Exp Therapeutics</I>.
   <B>1995</B>;<I>272(2)</I>:939-44. <A NAME=r152></A></LI>
   
   <LI>von Moltke LL, Greenblatt DJ, et al. Inhibition of alprazolam
   and desipramine hydroxylation in vitro by paroxetine and
   fluvoxamine: comparison with other selective serotonin reuptake
   inhibitor antidepressants. <I>J Clin Psychopharmacol</I>.
   <B>1995</B>;<I>15(2)</I>:125-31. <A NAME=r153></A></LI>
   
   <LI>Lee HS, Jin C, et al. Modulation of cytochrome P450 activities
   by 7,8-benzoflavone and its metabolites. <I>Biochem &amp; Mol Bio
   Int</I>. <B>1994</B>;<I>34(3)</I>:483-91. <A NAME=r154></A></LI>
   
   <LI>Ronis MJ, Ingelman-Sundberg M, Badger TM. Induction,
   suppression and inhibition of multiple hepatic cytochrome P450
   isozymes in the male rat and bobwhite quail (Colinus virginianus)
   by ergosterol biosynthesis inhibiting fungicides (EBIFs).
   <I>Biochem Pharmacol</I>. <B>1994</B>;<I>48(10)</I>:1953-65.
   <A NAME=r155></A></LI>
   
   <LI>Jerling M, Merle Y, et al. Population pharmacokinetics of
   nortiptyline during monotherapy and during concomitant treatment
   with drugs that inhibit CYP2D6 -- an evaluation with the
   nonparametric maximum likelihood method. <I>Br J Clin
   Pharmacol</I>. <B>1994</B>;<I>38(5)</I>:453-62.
   <A NAME=r156></A></LI>
   
   <LI>Rowland K, Yeo WW, et al. Inhibition of CYP2D6 activity by
   treatment with propranolol and the role of 4-hydroxy propranolol.
   <I>Br J Clin Pharmacol</I>. <B>1994</B>;<I>38(1)</I>:9-14.
   <A NAME=r157></A></LI>
   
   <LI>Pellinen P, Honkakoski P, et al. Cocaine N-demethylation and
   the metabolism-related hepatotoxicity can be prevented by
   cytochrome P450 3A inhibitors. <I>Eur J Pharmacol</I>.
   <B>1994</B>;<I>270(1)</I>:35-43. <A NAME=r158></A></LI>
   
   <LI>Murray M, Butler AM, Stupans I. Competitive inhibition of
   human liver microsomal cytochrome P450 3A dependent steroid 6
   beta-hydroxylation activity by cyclophosphamide and ifosfamide in
   vitro. <I>J Pharmacol &amp; Exp Therapeutics</I>.
   <B>1994</B>;<I>270(2)</I>:645-9. <A NAME=r159></A></LI>
   
   <LI>Meschter CL, Mico BA, et al. A 13-week toxicologic and
   pathologic evaluation of prolonged cytochromes P450 inhibition by
   1-aminobenzotriazole in male rats. <I>Fundamental &amp; Applied
   Toxicol</I>. <B>1994</B>;<I>22(3)</I>:369-81.
   <A NAME=r160></A></LI>
   
   <LI>Leemann T, Bonnabry P, Dayer P. Selective inhibition of major
   drug metabolizing cytochrome P450 isozymes in human liver
   microsomes by carbon monoxide. <I>Life Sci</I>.
   <B>1994</B>;<I>54(14)</I>:951-6. <A NAME=r161></A></LI>
   
   <LI>Bornheim LM, Everhart ET, et al. Characterization of
   cannabidiol-mediated cytochrome P450 inactivation. <I>Biochem
   Pharmacol</I>. <B>1993</B>;<I>45(6)</I>:1323-31.
   <A NAME=r162></A></LI>
   
   <LI>Wu D, Otton SV, et al. Inhibition of human cytochrome P450 2D6
   (CYP2D6) by methadone. <I>Br J Clin Pharmacol</I>.
   <B>1993</B>;<I>35(1)</I>:30-4. <A NAME=r163></A></LI>
   
   <LI>LaBella FS, Queen G. General anesthetics inhibit cytochrome
   P450 monooxygenases and arachidonic acid metabolism. <I>Can J
   Physiol &amp; Pharmacol</I>. <B>1993</B>;<I>71(1)</I>:48-53.
   <A NAME=r164></A></LI>
   
   <LI>Strobl GR, von Kruedener S, et al. Development of a
   pharmacophore for inhibition of human liver cytochrome P450 2D6:
   molecular modeling and inhibition studies. <I>J Medicinal
   Chem</I>. <B>1993</B>;<I>36(9)</I>:1136-45. <A NAME=r165></A></LI>
   
   <LI>Le Guellec C, Lacerelle B, et al. Inhibitory effects of
   anticancer drugs on dextromethorphan O-demethylase activity in
   human liver microsomes. <I>Cancer Chemotherapy &amp;
   Pharmacology</I>. <B>1993</B>;<I>32(6)</I>:491-5.
   <A NAME=r166></A></LI>
   
   <LI>Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by
   human liver microsomes. <I>Br J Clin Pharmacol</I>.
   <B>1992</B>;<I>34(3)</I>:256-61. <A NAME=r167></A></LI>
   
   <LI>Crewe HK, Lennard MS, et al. The effect of selective serotonin
   re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in
   human liver microsomes. <I>Br J Clin Pharmacol</I>.
   <B>1992</B>;<I>34(3)</I>:262-5. <A NAME=r168></A></LI>
   
   <LI>Hollander D, Pradas J, et al. High-dose dextromethorphan in
   amyotrophic lateral sclerosis: phase I safety and pharmacokinetic
   studies. <I>Ann Neurol</I>. <B>1994</B>;<I>36(6)</I>:920-4.
   <A NAME=r169></A></LI>
   
   <LI>Elliott K, Hynansky A, Inturrisi CE. Dextromethorphan
   attenuates and reverses analgesic tolerance to morphine.
   <I>Pain</I>. <B>1994</B>;<I>59(3)</I>:361-8.
   <A NAME=r170></A></LI>
   
   <LI>Koymans LM, Vermeulen NP, et al. A preliminary 3D model for
   cytochrome P450 2D6 constructed by homology model building. <I>J
   Computer Aided Mol Design</I>. <B>1993</B>;<I>7(3)</I>:281-9.
   <A NAME=r171></A></LI>
   
   <LI>Fischer V, Vogels B, et al. The antipsychotic clozapine is
   metabolized by the polymorphic human microsomal and recombinant
   cytochrome P450 2D6. <I>J Pharmacol &amp; Exp Therapeutics</I>.
   <B>1992</B>;<I>260(3)</I>:1355-60. <A NAME=r172></A></LI>
   
   <LI>Masimirembwa CM, Hasler JA, et al. Inhibitory effects of
   antiparasitic drugs on cytochrome P450 2D6. <I>Eur J Clin
   Pharmacol</I>. <B>1995</B>;<I>48(1)</I>:35-8.
   <A NAME=r173></A></LI>
   
   <LI>Fix AS, Wightman KA, O'Callaghan JP. Reactive gliosis induced
   by MK-801 in the rat posterior cingulate/retrosplenial cortex:
   GFAP evaluation by sandwich ELISA and immunocytochemistry.
   <I>Neurotoxicol.</I>. <B>1995</B>;<I>16(2)</I>:229-37.
   <A NAME=r174></A></LI>
   
   <LI>Fix AS, Wozniak DF, et al. Quantitative analysis of factors
   influencing neuronal necrosis induced by MK-801 in the rat
   posterior cingulate/retrosplenial cortex. <I>Brain Res.</I>.
   <B>1995 Oct 23</B>;<I>696(1-2)</I>:194-204. <A NAME=r175></A></LI>
   
   <LI>Farber NB, Foster J, et al. alpha-2 adrenergic agonists
   prevent MK-801 neurotoxicity. <I>Neuropsychopharmacology</I>.
   <B>1995 Jul</B>;<I>12(4)</I>:347-9. <A NAME=r176></A></LI>
   
   <LI>Feinberg I, Campbell IG, Marrs JC. Intraperitoneal dizocilpine
   induces cortical spike-wave seizure discharges in rats.
   <I>Neuroscience Letters</I>. <B>1995 Aug
   25</B>;<I>196(3)</I>:157-60. <A NAME=r177></A></LI>
   
   <LI>Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA
   antagonists: the controversy over their potential for adverse
   effects on cortical neuronal morphology &#91;Review&#93;. <I>Acta
   Neurochirurgica - Supplementum</I>. <B>1994</B>;<I>60</I>:15-9.
   <A NAME=r178></A></LI>
   
   <LI>Martin P, Svensson A, et al. On the roles of dopamine D-1 vs.
   D-2 receptors for the hyperactivity response elicited by MK-801.
   <I>J. Neural Transmission</I>. <B>1994</B>;<I>95(2)</I>:113-21.
   <A NAME=r179></A></LI>
   
   <LI>Freeman JK, Goldberg MP. Confocal microscopic visualization of
   MK-801-induced cytoplasmic vacuoles in vitro.
   <I>Psychopharmacology Bulletin</I>.
   <B>1994</B>;<I>30(4)</I>:541-7. <A NAME=r180></A></LI>
   
   <LI>Jaatinen P, Kiianmaa K, et al. Ethanol-induced vacuolation in
   rat peripheral nervous system. <I>J. Autonomic Nervous Sys</I>.
   <B>1994 Jan-Feb</B>;<I>46(1-2)</I>:107-21. <A NAME=r181></A></LI>
   
   <LI>Cubells JF, Rayport S, et al. Methamphetamine neurotoxicity
   involves vacuolation of endocytic organelles and dopamine
   dependent intracellular oxidative stress. <I>J. Neurosci.</I>.
   <B>1994 Apr</B>;<I>14(4)</I>:2260-71. <A NAME=r182></A></LI>
   
   <LI>Auer RN, Coulter KC. The nature and time course of neuronal
   vacuolation induced by the N-methyl-D-aspartate antagonist MK-801.
   <I>Acta Neuropathologica</I>. <B>1994</B>;<I>87(1)</I>:1-7.
   <A NAME=r183></A></LI>
   
   <LI>Kilander K, Williams H. Yohimbine reduces neuropathology
   induced by ketamine/xylazine anesthesia. <I>Physiology &amp;
   Behavior</I>. <B>1992 Mar</B>;<I>51(3)</I>:657-9.
   <A NAME=r184></A></LI>
   
   <LI>Sury MR. Genital examination under ketamine sedation in cases
   of suspected sexual abuse &#91;letter; comment&#93;. <I>Archives
   of Disease in Childhood</I>. <B>1994 Nov</B>;<I>71(5)</I>:481.
   <A NAME=r185></A></LI>
   
   <LI>Rogers R, Murdoch LJ. Genital examination under ketamine
   sedation in cases of suspected sexual abuse &#91;letter;
   comment&#93;. <I>Archives of Disease in Childhood</I>. <B>1994
   Nov</B>;<I>71(5)</I>:481-482. <A NAME=r186></A></LI>
   
   <LI>Harari MD, Netzer D. Genital examination under ketamine
   sedation in cases of suspected sexual abuse. <I>Archives of
   Disease in Childhood</I>. <B>1994 Mar</B>;<I>70(3)</I>:197-9.
   <A NAME=r187></A></LI>
   
   <LI>Felser JM, Orban DJ. Dystonic reaction after ketamine abuse.
   <I>Ann. Emerg. Med.</I>. <B>1982 Dec</B>;<I>11(12)</I>:673-5.
   <A NAME=r188></A></LI>
   
   <LI>Ahmed SN, Petchovsky L. Abuse of ketamine &#91;letter&#93;.
   <I>Brit. J. Psychiatry</I>. <B>1980 Sep</B>;<I>137</I>:303.
   <A NAME=r189></A></LI>
   
   <LI>Anonymous. Ketamine abuse. <I>FDA Drug Bull.</I>. <B>1979
   Sep</B>;<I>9(4)</I>:24. <A NAME=r190></A></LI>
   
   <LI>Haigh JC. Use and abuse of drugs for chemical restraint of
   wildlife. <I>Vet. Clinics of N. Am.</I>. <B>1978
   May</B>;<I>8(2)</I>:343-52. <A NAME=r191></A></LI>
   
   <LI>Cosgrove J, Newell TG. Recovery of neuropsychological
   functions during reduction in use of phencyclidine. <I>J. Clin.
   Psychol.</I>. <B>1991 Jan</B>;<I>47(1)</I>:159-69.
   <A NAME=r192></A></LI>
   
   <LI>Thombs DL. A review of PCP abuse trends and perceptions.
   &#91;Review&#93;. <I>Public Health Reports</I>. <B>1989
   Jul-Aug</B>;<I>104(4)</I>:325-8. <A NAME=r193></A></LI>
   
   <LI>McCardle L, Fishein DH. The self-reported effects of PCP on
   human aggression. <I>Addictive Behav.</I>.
   <B>1989</B>;<I>14(4)</I>:465-72. <A NAME=r194></A></LI>
   
   <LI>Gorelick DA, Wilkins JN, Wong C. Outpatient treatment of PCP
   abusers. <I>Am. J. Drug &amp; Alcohol Abuse</I>.
   <B>1989</B>;<I>15(4)</I>:367-74. <A NAME=r195></A></LI>
   
   <LI>Wright HH, Cole EA, et al. Phencyclidine-induced psychosis:
   eight-year follow-up of ten cases. <I>S. Med. J.</I>. <B>1988
   May</B>;<I>81(5)</I>:565-7. <A NAME=r196></A></LI>
   
   <LI>Lue LP, Scimeca JA, et al. Pyrolitic fate of
   piperidinocyclohexanecarbonitrile, a contaminant of phencyclidine,
   during smoking. <I>J. Analytical Toxicol.</I>. <B>1988
   Mar-Apr</B>;<I>12(2)</I>:57-61. <A NAME=r197></A></LI>
   
   <LI>Giannini AJ, Loiselle RH, et al. Augmentation of haloperidol
   by ascorbic acid in phencyclidine intoxication. <I>Am. J.
   Psychiatry</I>. <B>1987 Sep</B>;<I>144(9)</I>:1207-9.
   <A NAME=r198></A></LI>
   
   <LI>Golden NL, Kuhnert BR, et al. Neonatal manifestations of
   maternal phencyclidine exposure. <I>J. Perinatal Med.</I>.
   <B>1987</B>;<I>15(2)</I>:185-91. <A NAME=r199></A></LI>
   
   <LI>Foster HM, Narasimhachari N. Phencyclidine in CSF and serum: a
   case of attempted filicide by a mother without a history of
   substance abuse. <I>J. Clin. Psychiatry</I>. <B>1986
   Aug</B>;<I>47(8)</I>:428-9. <A NAME=r200></A></LI>
   
   <LI>Rosen AM, Mukherjee S, Shinbach K. The efficacy of ECT in
   phencyclidine-induced psychosis. <I>J. Clin. Psychiatry</I>.
   <B>1984 May</B>;<I>45(5)</I>:220-2. <A NAME=r201></A></LI>
   
   <LI>Jacob MS, Carlen PL, et al. Phencyclidine ingestion: drug
   abuse and psychosis. <I>Int. J. Addictions</I>. <B>1981
   May</B>;<I>16(4)</I>:749-58.. <A NAME=r202></A></LI>
   
   <LI>Graeven DB, Sharp JG. Initiation, motivation, and cessation of
   phencyclidine use. <I>J. Psychol.</I>. <B>1981
   May</B>;<I>108(1)</I>:43-57. <A NAME=r203></A></LI>
   
   <LI>Graeven DB, Sharp JG, Glatt S. Acute effects of phencyclidine
   (PCP) on chronic and recreational users. <I>Am. J. Drug &amp;
   Alcohol Abuse</I>. <B>1981</B>;<I>8(1)</I>:39-50.
   <A NAME=r204></A></LI>
   
   <LI>Hadjiconstantinou M, Rossetti ZL, et al. Dizocilpine enhances
   striatal tyrosine hydroxylase and aromatic L-amino acid
   decarboxylase activity. <I>Eur. J. Pharmacol.</I>. <B>1995 Mar
   15</B>;<I>289(1)</I>:97-101. <A NAME=r205></A></LI>
   
   <LI>Lannes B, Bernard V, et al. Chronic treatment with dizocilpine
   maleate increases the number of striatal neurons expressing the D2
   receptor gene. <I>Neurosci.</I>. <B>1995
   Mar</B>;<I>65(2)</I>:431-8. <A NAME=r206></A></LI>
   
   <LI>Patel TR, McCulloch J. AMPA receptor antagonism attenuates
   MK-801-induced hypermetabolism in the posterior cingulate cortex.
   <I>Brain Res.</I>. <B>1995 Jul 24</B>;<I>686(2)</I>:254-8.
   <A NAME=r207></A></LI>
   
   <LI>Riepe MW, Hori N, et al. Failure of neuronal ion exchange, not
   potentiated excitation, causes excitotoxicity after inhibition of
   oxidative phosphorylation. <I>Neuroscience</I>. <B>1995
   Jan</B>;<I>64(1)</I>:91-7. <A NAME=r208></A></LI>
   
   <LI>Papp M, Moryl E. Antidepressant activity of non-competitive
   and competitive NMDA receptor antagonists in a chronic mild stress
   model of depression. <I>Eur. J. Phrmacol.</I>. <B>1994 Sep
   22</B>;<I>263(1-2)</I>:1-7. <A NAME=r209></A></LI>
   
   <LI>Ogren SO, Goldstein M. Phencyclidine- and dizocipline-induced
   hyperlocomotion are differentially mediated.
   <I>Neuropsychopharmacol.</I>. <B>1994 Nov</B>;<I>11(3)</I>:167-77.
   <A NAME=r210></A></LI>
   
   <LI>Kinoshita H, Hasegawa T, et al. Competitive NMDA antagonists
   enhance the catalepsy induced by delta 9-tetrahydrocannabinol in
   mice. <I>Neurosci. Let.</I>. <B>1994 Jun
   6</B>;<I>174(1)</I>:101-4. <A NAME=r211></A></LI>
   
   <LI>Itzhak Y. Modulation of the PCP/NMDA receptor complex and
   sigma binding sites by psychostimulants. <I>Neurotoxicol. &amp;
   Teratol.</I>. <B>1994 Jul-Aug</B>;<I>16(4)</I>:363-8.
   <A NAME=r212></A></LI>
   
   <LI>Klimek V, Papp M. The effect of MK-801 and imipramine on
   beta-adrenergic and 5HT2 receptors in the chronic mild stress
   model of depression in rats. <I>Polish J. Pharmacol</I>. <B>1994
   Jan-Apr</B>;<I>46(1-2)</I>:67-9. <A NAME=r213></A></LI>
   
   <LI>Ellison G. Competitive and non-competitive NMDA antagonists
   induce similar limbic degeneration. <I>Neuroreport</I>. <B>1994
   Dec 20</B>;<I>5(18)</I>:2688-92. <A NAME=r214></A></LI>
   
   <LI>Thorat SN, Bhargava HN. Effects of NMDA receptor blockade and
   nitric oxide synthase inhibition on the acute and chronic actions
   of delta 9-tetrahydrocannabinol in rats. <I>77-82</I>. <B>1994 Dec
   19</B>;<I>667(1)</I><A NAME=r215></A></LI>
   
   <LI>Wessinger WD. Tolerance to and dependence on MK-801
   (dizocilpine) in rats. <I>Pharmacol., Biochem. &amp; Behav.</I>.
   <B>1994 Dec</B>;<I>49(4)</I>:1049-56. <A NAME=r216></A></LI>
   
   <LI>Brouillet E, Henshaw DR, et al. Aminooxyacetic acid striatal
   lesions attenuated by 1,3-butanediol and coenzyme Q10.
   <I>Neurosci. Lett.</I>. <B>1994 Aug 15</B>;<I>177(1-2)</I>:58-62.
   <A NAME=r217></A></LI>
   
   <LI>Fix AS, Horn JW, et al. Neuronal vacuole formation in the rat
   posterior cingulate/retrosplenial cortex after treatment with the
   N-methyl-D-aspartate (NMDA) antagonist MK-801 (dizocilpine
   maleate). <I>Acta Neurophatologica</I>.
   <B>1994</B>;<I>88(6)</I>:511-9. <A NAME=r218></A></LI>
   
   <LI>Mailleux P, Vanderhaeghen JJ. Glutamatergic regulation of
   cannabinoid receptor gene expression in the caudate-putamen.
   <I>Eur. J. Pharmacol.</I>. <B>1994 Jan 15</B>;<I>226(2)</I>:193-6.
   <A NAME=r219></A></LI>
   
   <LI>Berger P, Farrel K, et al. Drugs acting at the
   strychnine-insensitive glycine receptor do not induce HSP-70
   protein in the cingulate cortex. <I>Neurosci. Lett.</I>. <B>1994
   Feb 28</B>;<I>168(1-2)</I>:147-50. <A NAME=r220></A></LI>
   
   <LI>Vornov JJ, Tasker RC, Coyle JT. Delayed protection by MK-801
   and tetrodotoxin in a rat organotypic hippocampal culture model of
   ischemia. <I>Stroke</I>. <B>1994 Feb</B>;<I>25(2)</I>:457-64.
   <A NAME=r221></A></LI>
   
   <LI>Gauer F, Masson-Pevet M, Pevet P. The NMDA antagonist MK-801
   blocks light effect on melatonin receptor density in rat
   suprachiasmatic nuclei. <I>Neurosci. Lett.</I>. <B>1994 Apr
   25</B>;<I>171(1-2)</I>:24-6. <A NAME=r222></A></LI>
   
   <LI>Akunne HC, Monn JA, et al. An electrophilic affinity ligand
   based on (+)-MK801 distinguishes PCP site 1 from PCP site 2.
   <I>Neurochemical Res.</I>. <B>1994 Apr</B>;<I>19(4)</I>:385-9.
   <A NAME=r223></A></LI>
   
   <LI>Papp M, Moryl E. New evidence for the antidepressant activity
   of MK-801, a non-competitive antagonist of NMDA receptors.
   <I>Polish J. Pharmacol.</I>. <B>1993
   Sep-Dec</B>;<I>45(5-6)</I>:549-53.. <A NAME=r224></A></LI>
   
   <LI>Sun X, Larson AA. MK-801 inhibits the effects of capsaicin in
   the adult mouse by an action involving phencyclidine (PCP) sites
   not linked to NMDA activity. <I>Neuroreport</I>. <B>1993 Sep
   3</B>;<I>4(10)</I>:1147-50. <A NAME=r225></A></LI>
   
   <LI>Panconi E, Roux J, et al. MK-801 and enantiomers: potential
   antidepressants or false positives in classical screening models?.
   <I>Pharmacol., Biochem. &amp; Behav.</I>. <B>1993
   Sep</B>;<I>46(1)</I>:15-20. <A NAME=r226></A></LI>
   
   <LI>Wedzony K, Golembiowska K. Concomitant administration of
   MK-801 and desipramine enhances extracellular concentration of
   dopamine in the rat prefrontal cortex. <I>Neuroreport</I>. <B>1993
   Oct 25</B>;<I>5(1)</I>:75-7. <A NAME=r227></A></LI>
   
   <LI>Wedzony K, Golembiowska K, Klimek V. MK-801-induced symptoms
   of sensitization. The lack of correlation with the extracellular
   concentration of dopamine in the rat prefrontal cortex. <I>Brain
   Res.</I>. <B>1993 Oct 22</B>;<I>625(2)</I>:333-6.
   <A NAME=r228></A></LI>
   
   <LI>Layer RT, Bland LR, Skolnick P. MK-801, but not drugs acting
   at strychnine-insensitive glycine receptors, attenuate
   methamphetamine nigrostriatal toxicity. <I>Brain Res.</I>. <B>1993
   Oct 15</B>;<I>625(1)</I>:38-44. <A NAME=r229></A></LI>
   
   <LI>Meloni D, Gambarana C, et al. Dizocilpine antagonizes the
   effect of chronic imipramine on learned helplessness in rats.
   <I>Pharmacol., Biochem. &amp; Behav.</I>. <B>1993
   Oct</B>;<I>46(2)</I>:423-6. <A NAME=r230></A></LI>
   
   <LI>Rea MA, Buckley B, Lutton LM. Local administration of EAA
   antagonists blocks light-induced phase shifts and c-fos expression
   in hamster SCN. <I>Am. J. Phsyiol.</I>. <B>1993 Nov</B>;<I>265(5
   pt 2)</I>:1191-8. <A NAME=r231></A></LI>
   
   <LI>Agnew WF, McCreeny DB, et al. MK-801 protects against neuronal
   injury induced by electrical stimulation. <I>Neurosci.</I>.
   <B>1993 Jan</B>;<I>52(1)</I>:45-53. <A NAME=r232></A></LI>
   
   <LI>Wu PH, Mihic SJ, et al. Blockade of chronic tolerance to
   ethanol by the NMDA antagonist, (+)-MK-801. <I>Eur. J.
   Pharmacol.</I>. <B>1993 Feb 9</B>;<I>231(2)</I>:157-64.
   <A NAME=r233></A></LI>
   
   <LI>Magnusson KR, Cotman CW. Effects of aging on NMDA and MK801
   binding sites in mice. <I>Brain Res.</I>. <B>1993 Feb
   26</B>;<I>604(1-2)</I>:334-7. <A NAME=r234></A></LI>
   
   <LI>Wieraszko A, Ball GF. Long-term potentiation in the avian
   hippocampus does not require activation of the
   N-methyl-D-aspartate (NMDA) receptor. <I>Synapse</I>. <B>1993
   Feb</B>;<I>13(2)</I>:173-8. <A NAME=r235></A></LI>
   
   <LI>Akinci MK, Johnston GA. Sex differences in acute swim
   stress-induced changes in the binding of MK-801 to the NMDA
   subclass of glutamate receptors in mouse forebrain. <I>J.
   Neurochem.</I>. <B>1993 Dec</B>;<I>61(6)</I>:2290-3.
   <A NAME=r236></A></LI>
   
   <LI>Carlezon WA Jr, Wise RA. Morphine-induced potentiation of
   brain stimulation reward is enhanced by MK-801. <I>Brain Res.</I>.
   <B>1993 Aug 27</B>;<I>620(2)</I>:339-42. <A NAME=r237></A></LI>
   
   <LI>O'Donoghue DL, Poff CR, Block JJ. Chronic neonatal
   N-methyl-D-aspartate receptor antagonism with MK-801 increases the
   number of corticospinal cells retained into adulthood in the rat.
   <I>Neurosci. Lett.</I>. <B>1993 Aug 20</B>;<I>158(2)</I>:143-6.
   <A NAME=r238></A></LI>
   
   <LI>Ben-Eliyahu S, Page GG, et al. The NMDA receptor antagonist
   MK-801 blocks nonopioid stress induced analgesia and decreases
   tumor metastasis in the rat. <I>Proceed. Western Pharmacol.
   Soc.</I>. <B>1993</B>;<I>36</I>:293-8. <A NAME=r239></A></LI>
   
   <LI>Hoffman DC, Donovan H, Cassella JV. The effects of haoperidol
   and clozapine on the disruption of sensorimotor gating induced by
   the noncompetitive glutamate antagonist MK-801.
   <I>Psychopharmacol.</I>. <B>1993</B>;<I>111(3)</I>:339-44.
   <A NAME=r240></A></LI>
   
   <LI>Kasparov SA, Chizh BA. The NMDA-receptor antagonist
   dizocilpine (MK-801) suppresses the memory facilitatory action of
   thyrotropin-releasing hormone. <I>Neuropeptides</I>. <B>1992
   Oct</B>;<I>23(2)</I>:87-92. <A NAME=r241></A></LI>
   
   <LI>Farfel GM, Vosmer GL, Seiden LS. The N-methyl-D-aspartate
   antagonist MK-801 protects against serotonin depletions induced by
   methamphetamine, 3,4-methylenedioxymethamphetamine and
   p-chloroamphetamine. <I>Brain Res.</I>. <B>1992 Nov
   6</B>;<I>595(1)</I>:121-7. <A NAME=r242></A></LI>
   
   <LI>Simon DK, Prusky GT, O'Leary DD. N-methyl-D-aspartate receptor
   antagonists disrupt the formation of a mammalian neural map.
   <I>Proceedings of the National Acadamy of Sciences of the United
   States of America</I>. <B>1992 Nov 15</B>;<I>89(22)</I>:10593-7.
   <A NAME=r243></A></LI>
   
   <LI>Tasker RC, Coyle JT, Vornov JJ. The regional vulnerability to
   hypoglycemia-induced neurotoxicity in organotypic hippocampal
   culture: protection by early tetrodotoxin or delayed MK-801. <I>J.
   Neurosci.</I>. <B>1992 Nov</B>;<I>22(11)</I>:4298-308.
   <A NAME=r244></A></LI>
   
   <LI>Gandolfi O, Rimondini R, Dall'Olio R. The modulation of
   dopaminergic transmission in the striatum by MK-801 is independent
   of presynaptic mechanisms. <I>Neuropharmacol.</I>. <B>1992
   Nov</B>;<I>31(11)</I>:1111-4. <A NAME=r245></A></LI>
   
   <LI>Maj J, Rogoz Z, Skuza G. The effects of combined treatment
   with MK-801 and antidepressant drugs in the forced swimming test
   in rats. <I>Polish J. Pharmacol &amp; Pharmacy</I>. <B>1992
   May-Jun</B>;<I>44(3)</I>:217-26. <A NAME=r246></A></LI>
   
   <LI>Gorter JA, de Bruin JP. Chronic neonatal MK-801 treatment
   results in an impairment of spatial learning in the adult rat.
   <I>Brain Res.</I>. <B>1992 May 15</B>;<I>580(1-2)</I>:12-7.
   <A NAME=r247></A></LI>
   
   <LI>De Montis MG, Devoto P, et al. NMDA receptor inhibition
   prevents tolerance to cocaine. <I>Pharmacol., Biochem. &amp;
   Behav.</I>. <B>1992 May</B>;<I>42(1)</I>:179-82.
   <A NAME=r248></A></LI>
   
   <LI>Ben-Eliyahu S, Marek P, et al. The NMDA receptor antagonist
   MK-801 prevents long-lasting non-associative morphine tolerance in
   the rat. <I>Brain Res.</I>. <B>1992 Mar
   20</B>;<I>575(2)</I>:304-8. <A NAME=r249></A></LI>
   
   <LI>Shoaib M, Stolerman IP. MK-801 attenuates behavioural
   adaptation to chronic nicotine administration in rats. <I>Brit. J.
   Pharmacol.</I>. <B>1992 Mar</B>;<I>105(3)</I>:514-5.
   <A NAME=r250></A></LI>
   
   <LI>Maj J, Rogoz Z, et al. Effects of MK-801 and antidepressant
   drugs in the forced swimming test in rats. <I>Eur.
   Neuropharmacol.</I>. <B>1992 Mar</B>;<I>2(1)</I>:37-41.
   <A NAME=r251></A></LI>
   
   <LI>Shapiro ML, O'Connor C. N-methyl-D-aspartate receptor
   antagonist MK-801 and spatial memory representation: working
   memory is impaired in an unfamiliar environment but not in a
   familiar environment. <I>Behav. Neurosci.</I>. <B>1992
   Aug</B>;<I>106(4)</I>:604-12. <A NAME=r252></A></LI>
   
   <LI>Whitton PS, Biggs CS, et al. MK-801 increases extracellular
   5-hydroxytryptamine in rat hippocampus and striatum in vivo. <I>J.
   Neurochem.</I>. <B>1992 Apr</B>;<I>58(4)</I>:1573-5.
   <A NAME=r253></A></LI>
   
   <LI>Behrens S, Gattaz WF. MK-801 induced stereotypies in rats are
   decreased by haloperidol and increased by diazepam. <I>J. Neural
   Transmission</I>. <B>1992</B>;<I>90(3)</I>:219-24.
   <A NAME=r254></A></LI>
   
   <LI>Higgins GA, Nguyen P, Sellers EM. The NMDA antagonist
   dizocilpine (MK-801) attenuates motivational as well as somatic
   aspects of naloxone precipitated opioid withdrawal. <I>Life
   Sci.</I>. <B>1992</B>;<I>50(21)</I>:PL167-72.
   <A NAME=r255></A></LI>
   
   <LI>Murase S, Nisell M, et al. Decreased sensory responsiveness of
   noradrenergic neurons in the rat locus coeruleus following
   phencyclidine or dizocilpine (MK-801): role of NMDA antagonism.
   <I>Psychopharmacol.</I>. <B>1992</B>;<I>109(3)</I>:271-6.
   <A NAME=r256></A></LI>
   
   <LI>Steardo L, Monteleone P, d'Istria M, Serino I, Maj M, Cuomo V.
   Sigma receptor modulation of noradrenergic-stimulated pineal
   melatonin biosynthesis in rats. <I>Journal of Neurochemistry</I>.
   <B>1996 Jul</B>;<I>67(1)</I>:287-93. <A NAME=r257></A></LI>
   
   <LI>Whitlock BB, Liu Y, Chang S, Saini P, Ha BK, Barrett TW, Wolfe
   SA Jr. Initial characterization and autoradiographic localization
   of a novel sigma/opioid binding site in immune tissues. <I>Journal
   of Neuroimmunology</I>. <B>1996 Jul</B>;<I>67(2)</I>:83-96.
   <A NAME=r258></A></LI>
   
   <LI>Bergeron R, de Montigny C, Debonnel G. Potentiation of
   neuronal NMDA response induced by dehydroepiandrosterone and its
   suppression by progesterone: effects mediated via sigma receptors.
   <I>Journal of Neuroscience</I>. <B>1996 Feb
   1</B>;<I>16(3)</I>:1193-202. <A NAME=r259></A></LI>
   
   <LI>Debonnel G, Bergeron R, Monnet FP, De Montigny C. Differential
   effects of sigma ligands on the N-methyl-D-aspartate response in
   the CA1 and CA3 regions of the dorsal hippocampus: effect of mossy
   fiber lesioning. <I>Neuroscience</I>. <B>1996
   Apr</B>;<I>71(4)</I>:977-87. <A NAME=r260></A></LI>
   
   <LI>Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic
   neurotransmissions by sigma ligands: possible implications for the
   treatment of psychiatric disorders. &#91;Review&#93;. <I>Life
   Sciences</I>. <B>1996</B>;<I>58(9)</I>:721-34.
   <A NAME=r261></A></LI>
   
   <LI>Samovilova NN, Prokazova NV. &#91;Search for an endogenous
   ligand for sigma receptors&#93;. &#91;RUSSIAN&#93;. <I>Voprosy
   Meditsinskoi Khimii</I>. <B>1995 Sep-Oct</B>;<I>41(5)</I>:9-13.
   <A NAME=r262></A></LI>
   
   <LI>Wyrick SD, Booth RG, Myers AM, Owens CE, Bucholtz EC, Hooper
   PC, Kula NS, Baldessarini RJ, Mailman RB.
   1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and related
   derivatives as ligands for the neuromodulatory sigma 3 receptor:
   further structure-activity relationships. <I>Journal of Medicinal
   Chemistry</I>. <B>1995 Sep 15</B>;<I>38(19)</I>:3857-64.
   <A NAME=r263></A></LI>
   
   <LI>Carayon P, Bouaboula M, Loubet JF, Bourrie B, Petitpretre G,
   Le Fur G, Casellas P. The sigma ligand SR 31747 prevents the
   development of acute graft-versus-host disease in mice by blocking
   IFN-gamma and GM-CSF mRNA expression. <I>International Journal of
   Immunopharmacology</I>. <B>1995 Sep</B>;<I>17(9)</I>:753-61.
   <A NAME=r264></A></LI>
   
   <LI>Gudelsky GA. Effects of sigma receptor ligands on the
   extracellular concentration of dopamine in the striatum and
   prefrontal cortex of the rat. <I>European Journal of
   Pharmacology</I>. <B>1995 Nov 24</B>;<I>286(3)</I>:223-8.
   <A NAME=r265></A></LI>
   
   <LI>Bertha CM, Vilner BJ, Mattson MV, Bowen WD, Becketts K, Xu H,
   Rothman RB, Flippen-Anderson JL, Rice KC. (E)-8-benzylidene
   derivatives of 2-methyl-5-(3-hydroxyphenyl)morphans: highly
   selective ligands for the sigma 2 receptor subtype. <I>Journal of
   Medicinal Chemistry</I>. <B>1995 Nov 24</B>;<I>38(24)</I>:4776-85.
   <A NAME=r266></A></LI>
   
   <LI>Steardo L, Monteleone P, d'Istria M, Serino I, Maj M, Cuomo V.
   (+)-N-allylnormetazocine enhances N-acetyltransferase activity and
   melatonin synthesis: preliminary evidence for a functional role of
   sigma receptors in the rat pineal gland. <I>Journal of
   Pharmacology &amp; Experimental Therapeutics</I>. <B>1995
   Nov</B>;<I>275(2)</I>:845-9. <A NAME=r267></A></LI>
   
   <LI>Chien CC, Pasternak GW. Sigma antagonists potentiate opioid
   analgesia in rats. <I>Neuroscience Letters</I>. <B>1995 May
   5</B>;<I>190(2)</I>:137-9. <A NAME=r268></A></LI>
   
   <LI>Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB-184:
   ligands with high sigma 2 receptor affinity and subtype
   selectivity. <I>European Journal of Pharmacology</I>. <B>1995 May
   24</B>;<I>278(3)</I>:257-60. <A NAME=r269></A></LI>
   
   <LI>Brent PJ, Pang GT. Sigma binding site ligands inhibit cell
   proliferation in mammary and colon carcinoma cell lines and
   melanoma cells in culture. <I>European Journal of
   Pharmacology</I>. <B>1995 May 15</B>;<I>278(2)</I>:151-60.
   <A NAME=r270></A></LI>
   
   <LI>Schoenwald RD, Barfknecht CF, Shirolkar S, Xia E. The effects
   of sigma ligands on protein release from lacrimal acinar cells: a
   potential agonist/antagonist assay. <I>Life Sciences</I>. <B>1995
   Mar 3</B>;<I>56(15)</I>:1275-85. <A NAME=r271></A></LI>
   
   <LI>Bergeron R, de Montigny C, Debonnel G. Biphasic effects of
   sigma ligands on the neuronal response to N-methyl-D-aspartate.
   <I>Naunyn-Schmiedebergs Archives of Pharmacology</I>. <B>1995
   Mar</B>;<I>351(3)</I>:252-60. <A NAME=r272></A></LI>
   
   <LI>Bastianetto S, Rouquier L, Perrault G, Sanger DJ. DTG-induced
   circling behaviour in rats may involve the interaction between
   sigma sites and nigro-striatal dopaminergic pathways.
   <I>Neuropharmacology</I>. <B>1995 Mar</B>;<I>34(3)</I>:281-7.
   <A NAME=r273></A></LI>
   
   <LI>Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME,
   Jacobson AE. Ibogaine and its congeners are sigma 2
   receptor-selective ligands with moderate affinity. <I>European
   Journal of Pharmacology</I>. <B>1995 Jun 6</B>;<I>279(1)</I>:R1-3.
   <A NAME=r274></A></LI>
   
   <LI>Liu Y, Whitlock BB, et al. Sigma-1 receptors modulate
   functional activity of rat splenocytes. <I>J. Neuroimmunology</I>.
   <B>1995 Jun</B>;<I>59(1-2)</I>:143-54. <A NAME=r275></A></LI>
   
   <LI>Yamamoto H, Yamamoto T, Sagi N, Klenerova V, Goji K, Kawai N,
   Baba A, Takamori E, Moroji T. Sigma ligands indirectly modulate
   the NMDA receptor-ion channel complex on intact neuronal cells via
   sigma 1 site. <I>Journal of Neuroscience</I>. <B>1995
   Jan</B>;<I>15(1 Pt 2)</I>:731-6. <A NAME=r276></A></LI>
   
   <LI>Gonzalez-Alvear GM, Werling LL. Sigma receptor regulation of
   norepinephrine release from rat hippocampal slices. <I>Brain
   Research</I>. <B>1995 Feb 27</B>;<I>673(1)</I>:61-9.
   <A NAME=r277></A></LI>
   
   <LI>Weiser SD, Patrick SL, Mascarella SW, Downing-Park J, Bai X,
   Carroll FI, Walker JM, Patrick RL. Stimulation of rat striatal
   tyrosine hydroxylase activity following intranigral administration
   of sigma receptor ligands. <I>European Journal of
   Pharmacology</I>. <B>1995 Feb 24</B>;<I>275(1)</I>:1-7.
   <A NAME=r278></A></LI>
   
   <LI>Kreeger JS, Yukhananov RYu, Larson AA. Altered
   N-methyl-D-aspartate (NMDA) activity in the mouse spinal cord
   following morphine is mediated by sigma activity. <I>Brain
   Research</I>. <B>1995 Feb 20</B>;<I>672(1-2)</I>:83-8.
   <A NAME=r279></A></LI>
   
   <LI>Church J, Fletcher EJ. Blockade by sigma site ligands of high
   voltage-activated Ca2+ channels in rat and mouse cultured
   hippocampal pyramidal neurones. <I>British Journal of
   Pharmacology</I>. <B>1995 Dec</B>;<I>116(7)</I>:2801-10.
   <A NAME=r280></A></LI>
   
   <LI>Fletcher EJ, Church J, Abdel-Hamid K, MacDonald JF. Blockade
   by sigma site ligands of N-methyl-D-aspartate-evoked responses in
   rat and mouse cultured hippocampal pyramidal neurones. <I>British
   Journal of Pharmacology</I>. <B>1995
   Dec</B>;<I>116(7)</I>:2791-800. <A NAME=r281></A></LI>
   
   <LI>Gonzalez-Alvear GM, Thompson-Montgomery D, Deben SE, Werling
   LL. Functional and binding properties of sigma receptors in rat
   cerebellum. <I>Journal of Neurochemistry</I>. <B>1995
   Dec</B>;<I>65(6)</I>:2509-16. <A NAME=r282></A></LI>
   
   <LI>Kest B, Mogil JS, Sternberg WF, Pechnick RN, Liebeskind JC.
   Antinociception following 1,3,-di-o-tolylguanidine, a selective
   sigma receptor ligand. <I>Pharmacology, Biochemistry &amp;
   Behavior</I>. <B>1995 Apr</B>;<I>50(4)</I>:587-92.
   <A NAME=r283></A></LI>
   
   <LI>Mach RH, Smith CR, Childers SR. Ibogaine possesses a selective
   affinity for sigma 2 receptors. <I>Life Sciences</I>.
   <B>1995</B>;<I>57(4)</I>:PL57-62. <A NAME=r284></A></LI>
   
   <LI>Pechnick RN, Poland RE. Neuroendocrine responses produced by
   enantiomeric pairs of drugs that interact with phencyclidine and
   sigma receptors. <I>European Journal of Pharmacology</I>. <B>1994
   Sep 22</B>;<I>263(1-2)</I>:115-20. <A NAME=r285></A></LI>
   
   <LI>Bonhaus DW, Loury DN, et al. &#91;3H&#93;RS-23597-190, a
   potent 5-hydroxytryptamine4 antagonist labels sigma-1 but not
   sigma-2 binding sites in guinea pig brain. <I>J. Pharmacol. &amp;
   Exp. Therapeutics</I>. <B>1994 Oct</B>;<I>271(1)</I>:484-93.
   <A NAME=r286></A></LI>
   
   <LI>Nyberg L, McIntosh AR, Cabeza R, Nilsson LG, Houle S, Habib R,
   Tulving E. Network analysis of positron emission tomography
   regional cerebral blood flow data: ensemble inhibition during
   episodic memory retrieval. <I>Journal of Neuroscience</I>. <B>1996
   Jun 1</B>;<I>16(11)</I>:3753-9. <A NAME=r287></A></LI>
   
   <LI>Ho AP, Gillin JC, Buchsbaum MS, Wu JC, Abel L, Bunney WE Jr.
   Brain glucose metabolism during non-rapid eye movement sleep in
   major depression. A positron emission tomography study.
   <I>Archives of General Psychiatry</I>. <B>1996
   Jul</B>;<I>53(7)</I>:645-52. <A NAME=r288></A></LI>
   
   <LI>Gyulai FE, Firestone LL, Mintun MA, Winter PM. In vivo imaging
   of human limbic responses to nitrous oxide inhalation.
   <I>Anesthesia &amp; Analgesia</I>. <B>1996
   Aug</B>;<I>83(2)</I>:291-8. <A NAME=r289></A></LI>
   
   <LI>Fix AS, Wightman KA, O'Callaghan JP. Reactive gliosis induced
   by MK-801 in the rat posterior cingulate/retrosplenial cortex:
   GFAP evaluation by sandwich ELISA and immunocytochemistry.
   <I>Neurotoxicology</I>. <B>1995 Summer</B>;<I>16(2)</I>:229-37.
   <A NAME=r290></A></LI>
   
   <LI>Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW.
   Quantitative analysis of factors influencing neuronal necrosis
   induced by MK-801 in the rat posterior cingulate/retrosplenial
   cortex. <I>Brain Research</I>. <B>1995 Oct
   23</B>;<I>696(1-2)</I>:194-204. <A NAME=r291></A></LI>
   
   <LI>Noga JT, Aylward E, Barta PE, Pearlson GD. Cingulate gyrus in
   schizophrenic patients and normal volunteers. <I>Psychiatry
   Research</I>. <B>1995 Nov 10</B>;<I>61(4)</I>:201-8.
   <A NAME=r292></A></LI>
   
   <LI>Fletcher PC, Happe F, Frith U, Baker SC, Dolan RJ, Frackowiak
   RS, Frith CD. Other minds in the brain: a functional imaging study
   of "theory of mind" in story comprehension. <I>Cognition</I>.
   <B>1995 Nov</B>;<I>57(2)</I>:109-28. <A NAME=r293></A></LI>
   
   <LI>Flugge G. Dynamics of central nervous 5-HT1A-receptors under
   psychosocial stress. <I>Journal of Neuroscience</I>. <B>1995
   Nov</B>;<I>15(11)</I>:7132-40. <A NAME=r294></A></LI>
   
   <LI>Yukie M. Neural connections of auditory association cortex
   with the posterior cingulate cortex in the monkey. <I>Neuroscience
   Research</I>. <B>1995 May</B>;<I>22(2)</I>:179-87.
   <A NAME=r295></A></LI>
   
   <LI>Stanton GB, Bruce CJ, Goldberg ME. Topography of projections
   to posterior cortical areas from the macaque frontal eye fields.
   <I>Journal of Comparative Neurology</I>. <B>1995 Mar
   6</B>;<I>353(2)</I>:291-305. <A NAME=r296></A></LI>
   
   <LI>Ishimaru M, Fukamauchi F, Olney JW. Halothane prevents MK-801
   neurotoxicity in the rat cingulate cortex. <I>Neuroscience
   Letters</I>. <B>1995 Jun 23</B>;<I>193(1)</I>:1-4.
   <A NAME=r297></A></LI>
   
   <LI>Sharp JW, Petersen DL, Langford MT. DNQX inhibits
   phencyclidine (PCP) and ketamine induction of the hsp70 heat shock
   gene in the rat cingulate and retrosplenial cortex. <I>Brain
   Research</I>. <B>1995 Jul 31</B>;<I>687(1-2)</I>:114-24.
   <A NAME=r298></A></LI>
   
   <LI>Hedberg TG, Stanton PK. Long-term potentiation and depression
   of synaptic transmission in rat posterior cingulate cortex.
   <I>Brain Research</I>. <B>1995 Jan 30</B>;<I>670(2)</I>:181-96.
   <A NAME=r299></A></LI>
   
   <LI>Fredrikson M, WIk G, Annas P, Ericson K, Stone-Elander S.
   Functional neuroanatomy of visually elicited simple phobic fear:
   additional data and theoretical analysis. <I>Psychophysiology</I>.
   <B>1995 Jan</B>;<I>32(1)</I>:43-8. <A NAME=r300></A></LI>
   
   <LI>Ellison G. The N-methyl-D-aspartate antagonists phencyclidine,
   ketamine and dizocilpine as both behavioral and anatomical models
   of the dementias. &#91;Review&#93;. <I>Brain Research - Brain
   Research Reviews</I>. <B>1995 Feb</B>;<I>20(2)</I>:250-67.
   <A NAME=r301></A></LI>
   
   <LI>Izumisawa N, Kawakami A, Ohata T, Hanada T, Okeda R. YM90K, an
   AMPA antagonist, has no neurotoxic effects on cerebrocortical
   neurons in rats. <I>Experimental Neurology</I>. <B>1995
   Aug</B>;<I>134(2)</I>:199-204. <A NAME=r302></A></LI>
   
   <LI>Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa
   SM, Swanson RA, Sagar SM. Phencyclidine induction of the hsp 70
   stress gene in injured pyramidal neurons is mediated via multiple
   receptors and voltage gated calcium channels. <I>Neuroscience</I>.
   <B>1994 Oct</B>;<I>62(4)</I>:1079-92. <A NAME=r303></A></LI>
   
   <LI>Bottini G, Corcoran R, Sterzi R, Paulesu E, Schenone P, Scarpa
   P, Frackowiak RS, Frith CD. The role of the right hemisphere in
   the interpretation of figurative aspects of language. A positron
   emission tomography activation study. <I>Brain</I>. <B>1994
   Dec</B>;<I>117 ( Pt 6)</I>:1241-53. <A NAME=r304></A></LI>
   
   <LI>Molchan SE, Sunderland T, McIntosh AR, Herscovitch P, Schreurs
   BG. A functional anatomical study of associative learning in
   humans. <I>Proceedings of the National Academy of Sciences of the
   United States of America</I>. <B>1994 Aug
   16</B>;<I>91(17)</I>:8122-6. <A NAME=r305></A></LI>
   
   <LI>McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan
   RJ. Functional anatomy of obsessive-compulsive phenomena.
   <I>British Journal of Psychiatry</I>. <B>1994
   Apr</B>;<I>164(4)</I>:459-68. <A NAME=r306></A></LI>
   
   <LI>Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA
   antagonists: the controversy over their potential for adverse
   effects on cortical neuronal morphology. &#91;Review&#93;. <I>Acta
   Neurochirurgica - Supplementum</I>. <B>1994</B>;<I>60</I>:15-9.
   <A NAME=r307></A></LI>
   
   <LI>Auer RN, Coulter KC. The nature and time course of neuronal
   vacuolation induced by the N-methyl-D-aspartate antagonist MK-801.
   <I>Acta Neuropathologica</I>. <B>1994</B>;<I>87(1)</I>:1-7.
   <A NAME=r308></A></LI>
   
   <LI>Fix AS, Horn JW, Truex LL, Smith RA, Gomez E. Neuronal vacuole
   formation in the rat posterior cingulate/retrosplenial cortex
   after treatment with the N-methyl-D-aspartate (NMDA) antagonist
   MK-801 (dizocilpine maleate). <I>Acta Neuropathologica</I>.
   <B>1994</B>;<I>88(6)</I>:511-9. <A NAME=r309></A></LI>
   
   <LI>Fix AS. Pathological effects of MK-801 in the rat posterior
   cingulate/retrosplenial cortex. &#91;Review&#93;.
   <I>Psychopharmacology Bulletin</I>.
   <B>1994</B>;<I>30(4)</I>:577-83. <A NAME=r310></A></LI>
   
   <LI>Schlaug G, Armstrong E, Schleicher A, Zilles K. Layer V
   pyramidal cells in the adult human cingulate cortex. A
   quantitative Golgi-study. <I>Anatomy &amp; Embryology</I>. <B>1993
   Jun</B>;<I>187(6)</I>:515-22. <A NAME=r311></A></LI>
   
   <LI>Hedberg TG, Simpson GV, Stanton PK. Microcircuitry of
   posterior cingulate cortex in vitro: electrophysiology and laminar
   analysis using the current source density method &#91;published
   erratum appears in Brain Res 1994 May 30;647(1):177-9&#93;.
   <I>Brain Research</I>. <B>1993 Dec 31</B>;<I>632(1-2)</I>:239-48.
   <A NAME=r312></A></LI>
   
   <LI>Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL.
   Competitive as well as uncompetitive N-methyl-D-aspartate receptor
   antagonists affect cortical neuronal morphology and cerebral
   glucose metabolism. <I>Neurochemical Research</I>. <B>1993
   Dec</B>;<I>18(12)</I>:1263-9. <A NAME=r313></A></LI>
   
   <LI>Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ.
   Regional cerebral blood flow in depression measured by positron
   emission tomography: the relationship with clinical dimensions.
   &#91;Review&#93;. <I>Psychological Medicine</I>. <B>1993
   Aug</B>;<I>23(3)</I>:579-90. <A NAME=r314></A></LI>
   
   <LI>Hof PR, Archin N, Osmand AP, Dougherty JH, Wells C, Bouras C,
   Morrison JH. Posterior cortical atrophy in Alzheimer's disease:
   analysis of a new case and re-evaluation of a historical report.
   <I>Acta Neuropathologica</I>. <B>1993</B>;<I>86(3)</I>:215-23.
   <A NAME=r315></A></LI>
   
   <LI>Olson CR, Musil SY. Topographic organization of cortical and
   subcortical projections to posterior cingulate cortex in the cat:
   evidence for somatic, ocular, and complex subregions. <I>Journal
   of Comparative Neurology</I>. <B>1992 Oct
   8</B>;<I>324(2)</I>:237-60. <A NAME=r316></A></LI>
   
   <LI>Olson CR, Musil SY. Posterior cingulate cortex: sensory and
   oculomotor properties of single neurons in behaving cat.
   <I>Cerebral Cortex</I>. <B>1992 Nov-Dec</B>;<I>2(6)</I>:485-502.
   <A NAME=r317></A></LI>
   
   <LI>Vogt BA, Crino PB, Vogt LJ. Reorganization of cingulate cortex
   in Alzheimer's disease: neuron loss, neuritic plaques, and
   muscarinic receptor binding. <I>Cerebral Cortex</I>. <B>1992
   Nov-Dec</B>;<I>2(6)</I>:526-35. <A NAME=r318></A></LI>
   
   <LI>Duval D, Roome N, Gauffeny C, Nowicki JP, Scatton B. SL
   82.0715, an NMDA antagonist acting at the polyamine site, does not
   induce neurotoxic effects on rat cortical neurons. <I>Neuroscience
   Letters</I>. <B>1992 Mar 30</B>;<I>137(2)</I>:193-7.
   <A NAME=r319></A></LI>
   
   <LI>Neave N, Lloyd S, Sahgal A, Aggleton JP. Lack of effect of
   lesions in the anterior cingulate cortex and retrosplenial cortex
   on certain tests of spatial memory in the rat. <I>Behavioural
   Brain Research</I>. <B>1994 Nov 16</B>;<I>65(1)</I>:89-101.
   <A NAME=r320></A></LI>
   
   <LI>Gage SL, Keim SR, Simon JR, Low WC. Cholinergic innervation of
   the retrosplenial cortex via the fornix pathway as determined by
   high affinity choline uptake, choline acetyltransferase activity,
   and muscarinic receptor binding in the rat. <I>Neurochemical
   Research</I>. <B>1994 Nov</B>;<I>19(11)</I>:1379-86.
   <A NAME=r321></A></LI>
   
   <LI>Tulving E, Markowitsch HJ, Kapur S, Habib R, Houle S. Novelty
   encoding networks in the human brain: positron emission tomography
   data. <I>Neuroreport</I>. <B>1994 Dec 20</B>;<I>5(18)</I>:2525-8.
   <A NAME=r322></A></LI>
   
   <LI>Gao XM, Shirakawa O, Du F, Tamminga CA. Delayed regional
   metabolic actions of phencyclidine. <I>European Journal of
   Pharmacology</I>. <B>1993 Sep 7</B>;<I>241(1)</I>:7-15.
   <A NAME=r323></A></LI>
   
   <LI>Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW,
   Farber N, Wozniak DF, Olney JW. Neuronal vacuolization and
   necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA)
   antagonist MK(+)801 (dizocilpine maleate): a light and electron
   microscopic evaluation of the rat retrosplenial cortex.
   <I>Experimental Neurology</I>. <B>1993
   Oct</B>;<I>123(2)</I>:204-15. <A NAME=r324></A></LI>
   
   <LI>Wyss JM, Van Groen T. Connections between the retrosplenial
   cortex and the hippocampal formation in the rat: a review.
   &#91;Review&#93;. <I>Hippocampus</I>. <B>1992
   Jan</B>;<I>2(1)</I>:1-11. <A NAME=r325></A></LI>
   
   <LI>Nakki R, Nickolenko J, Chang J, Sagar SM, Sharp FR.
   Haloperidol prevents ketamine- and phencyclidine-induced HSP70
   protein expression but not microglial activation. <I>Experimental
   Neurology</I>. <B>1996 Feb</B>;<I>137(2)</I>:234-41.
   <A NAME=r326></A></LI>
   
   <LI>Verma A, Moghaddam B. NMDA receptor antagonists impair
   prefrontal cortex function as assessed via spatial delayed
   alternation performance in rats: modulation by dopamine.
   <I>Journal of Neuroscience</I>. <B>1996
   Jan</B>;<I>16(1)</I>:373-9. <A NAME=r327></A></LI>
   
   <LI>Steinberg GK, Bell TE, Yenari MA. Dose escalation safety and
   tolerance study of the N-methyl-D-aspartate antagonist
   dextromethorphan in neurosurgery patients. <I>Journal of
   Neurosurgery</I>. <B>1996 May</B>;<I>84(5)</I>:860-6.
   <A NAME=r328></A></LI>
   
   <LI>Farber NB, Foster J, Duhan NL, Olney JW. alpha 2 adrenergic
   agonists prevent MK-801 neurotoxicity.
   <I>Neuropsychopharmacology</I>. <B>1995
   Jul</B>;<I>12(4)</I>:347-9. <A NAME=r329></A></LI>
   
   <LI>Olney JW. Neurotoxicity of NMDA receptor antagonists: an
   overview. &#91;Review&#93;. <I>Psychopharmacology Bulletin</I>.
   <B>1994</B>;<I>30(4)</I>:533-40. <A NAME=r330></A></LI>
   
   <LI>Persinger MA, Psych C. Sudden unexpected death in epileptics
   following sudden, intense, increases in geomagnetic activity:
   prevalence of effect and potential mechanisms. <I>International
   Journal of Biometeorology</I>. <B>1995 May</B>;<I>38(4)</I>:180-7.
   <A NAME=r331></A></LI>
   
   <LI>Persinger MA. On the possibility of directly accessing every
   human brain by electromagnetic induction of fundamental
   algorithms. <I>Perceptual &amp; Motor Skills</I>. <B>1995
   Jun</B>;<I>80(3 Pt 1)</I>:791-9. <A NAME=r332></A></LI>
   
   <LI>Persinger MA, Richards PM. Vestibular experiences of humans
   during brief periods of partial sensory deprivation are enhanced
   when daily geomagnetic activity exceeds 15-20 nT. <I>Neuroscience
   Letters</I>. <B>1995 Jul 14</B>;<I>194(1-2)</I>:69-72.
   <A NAME=r333></A></LI>
   
   <LI>Persinger MA. Out-of-body-like experiences are more probable
   in people with elevated complex partial epileptic-like signs
   during periods of enhanced geomagnetic activity: a nonlinear
   effect. <I>Perceptual &amp; Motor Skills</I>. <B>1995
   Apr</B>;<I>80(2)</I>:563-9. <A NAME=r334></A></LI>
   
   <LI>Persinger MA. Complex partial epileptic-like signs contribute
   differential sources of variance to low self-esteem and
   imaginings. <I>Perceptual &amp; Motor Skills</I>. <B>1995
   Apr</B>;<I>80(2)</I>:427-31. <A NAME=r335></A></LI>
   
   <LI>Persinger MA, Bureau YR, Peredery OP, Richards PM. The sensed
   presence as right hemispheric intrusions into the left hemispheric
   awareness of self: an illustrative case study &#91;see
   comments&#93;. <I>Perceptual &amp; Motor Skills</I>. <B>1994
   Jun</B>;<I>78(3 Pt 1)</I>:999-1009. <A NAME=r336></A></LI>
   
   <LI>Persinger MA, Richards PM, Koren SA. Differential ratings of
   pleasantness following right and left hemispheric application of
   low energy magnetic fields that stimulate long-term potentiation.
   <I>International Journal of Neuroscience</I>. <B>1994
   Dec</B>;<I>79(3-4)</I>:191-7. <A NAME=r337></A></LI>
   
   <LI>Tiller SG, Persinger MA. Enhanced hypnotizability by
   cerebrally applied magnetic fields depends upon the order of
   hemispheric presentation: an anistropic effect. <I>International
   Journal of Neuroscience</I>. <B>1994
   Dec</B>;<I>79(3-4)</I>:157-63. <A NAME=r338></A></LI>
   
   <LI>Tiller SG, Persinger MA. Elevated incidence of a sensed
   presence and sexual arousal during partial sensory deprivation and
   sensitivity to hypnosis: implications for hemisphericity and
   gender differences. <I>Perceptual &amp; Motor Skills</I>. <B>1994
   Dec</B>;<I>79(3 Pt 2)</I>:1527-31. <A NAME=r339></A></LI>
   
   <LI>Persinger MA. Sense of a presence and suicidal ideation
   following traumatic brain injury: indications of right-hemispheric
   intrusions from neuropsychological profiles. <I>Psychological
   Reports</I>. <B>1994 Dec</B>;<I>75(3 Pt 1)</I>:1059-70.
   <A NAME=r340></A></LI>
   
   <LI>Johnson CP, Persinger MA. The sensed presence may be
   facilitated by interhemispheric intercalation: relative efficacy
   of the Mind's Eye, Hemi-Sync Tape, and bilateral temporal magnetic
   field stimulation. <I>Perceptual &amp; Motor Skills</I>. <B>1994
   Aug</B>;<I>79(1 Pt 1)</I>:351-4. <A NAME=r341></A></LI>
   
   <LI>Skirda RJ, Persinger MA. Positive associations among dichotic
   listening errors, complex partial epileptic-like signs, and
   paranormal beliefs &#91;see comments&#93;. <I>Journal of Nervous
   &amp; Mental Disease</I>. <B>1993 Nov</B>;<I>181(11)</I>:663-7.
   <A NAME=r342></A></LI>
   
   <LI>Persinger MA. Vectorial cerebral hemisphericity as
   differential sources for the sensed presence, mystical experiences
   and religious conversions. &#91;Review&#93;. <I>Perceptual &amp;
   Motor Skills</I>. <B>1993 Jun</B>;<I>76(3 Pt 1)</I>:915-30.
   <A NAME=r343></A></LI>
   
   <LI>Persinger MA, Makarec K. Complex partial epileptic signs as a
   continuum from normals to epileptics: normative data and clinical
   populations. <I>Journal of Clinical Psychology</I>. <B>1993
   Jan</B>;<I>49(1)</I>:33-45. <A NAME=r344></A></LI>
   
   <LI>Persinger MA. Transcendental Meditation and general meditation
   are associated with enhanced complex partial epileptic-like signs:
   evidence for "cognitive" kindling?. <I>Perceptual &amp; Motor
   Skills</I>. <B>1993 Feb</B>;<I>76(1)</I>:80-2.
   <A NAME=r345></A></LI>
   
   <LI>Dittburner TL, Persinger MA. Intensity of amnesia during
   hypnosis is positively correlated with estimated prevalence of
   sexual abuse and alien abductions: implications for the false
   memory syndrome. <I>Perceptual &amp; Motor Skills</I>. <B>1993
   Dec</B>;<I>77(3 Pt 1)</I>:895-8. <A NAME=r346></A></LI>
   
   <LI>Persinger MA. Geophysical variables and behavior: LXXI.
   Differential contribution of geomagnetic activity to paranormal
   experiences concerning death and crisis: an alternative to the ESP
   hypothesis. <I>Perceptual &amp; Motor Skills</I>. <B>1993
   Apr</B>;<I>76(2)</I>:555-62. <A NAME=r347></A></LI>
   
   <LI>Persinger MA. Average diurnal changes in melatonin levels are
   associated with hourly incidence of bereavement apparitions:
   support for the hypothesis of temporal (limbic) lobe
   microseizuring. <I>Perceptual &amp; Motor Skills</I>. <B>1993
   Apr</B>;<I>76(2)</I>:444-6. <A NAME=r348></A></LI>
   
   <LI>Persinger MA, Makarec K. The feeling of a presence and verbal
   meaningfulness in context of temporal lobe function: factor
   analytic verification of the muses?. <I>Brain &amp; Cognition</I>.
   <B>1992 Nov</B>;<I>20(2)</I>:217-26. <A NAME=r349></A></LI>
   
   <LI>Persinger MA. Enhanced incidence of "the sensed presence" in
   people who have learned to meditate: support for the right
   hemispheric intrusion hypothesis. <I>Perceptual &amp; Motor
   Skills</I>. <B>1992 Dec</B>;<I>75(3 Pt 2)</I>:1308-10.
   <A NAME=r350></A></LI>
   
   <LI>Jaynes J. The origin of consciousness in the breakdown of the
   bicameral mind. Houghton Mifflin. <B>1977</B> (Boston)
   <A NAME=r351></A></LI>
   
   <LI>Bayorh MA, McGee LJ. Cardiovascular and hemodynamic effects of
   acute and chronic phencyclidine (PCP). <I>Res Comm Subs Abuse</I>.
   <B>1989</B>;<I>10(1)</I>:27-36. <A NAME=r352></A></LI>
   
   <LI>Rosenberg J, Pentel P, Pond S, benowitz N, Olson K.
   Hyperthermia associated with drug intoxication. <I>Crit Care
   Med</I>. <B>1986</B>;<I>14(11)</I>:964-9. <A NAME=r353></A></LI>
   
   <LI>Hoogwerf B, Kern J, Bullock M, Comty CM. Phencyclidine-induced
   rhabdomyolysis and acute renal failure. <I>Clin Toxicol</I>.
   <B>1979</B>;<I>14(1)</I>:47-53. <A NAME=r354></A></LI>
   
   <LI>Dunn JR, Fuller M, Zoeger J, et al. Magnetic material in the
   human hippocampus. <I>Brain Res Bull</I>.
   <B>1995</B>;<I>36(2)</I>:149-53. <A NAME=r355></A></LI>
   
   <LI>Perry PJ, Alexander B, Ellingrod VL. <A HREF="http://www.vh.org/Providers/Conferences/CPS/29.html">http://www.vh.org/Providers/Conferences/CPS/29.html</A>
   <A NAME=r356></A></LI>
   
   <LI>Crews DJ, Landers DM. Electroencephalographic measures of
   attentional patterns prior to the golf putt. <I>Medicine &amp;
   Science in Sports &amp; Exercise</I>. <B>1993
   Jan</B>;<I>25(1)</I>:116-26. <A NAME=r357></A></LI>
   
   <LI>Steffensen SC. Dehydroepiandrosterone sulfate suppresses
   hippocampal recurrent inhibition and synchronizes neuronal
   activity to theta rhythm. <I>Hippocampus</I>.
   <B>1995</B>;<I>5(4)</I>:320-8. <A NAME=r358></A></LI>
   
   <LI>Thinschmidt JS, Kinney GG, Kocsis B. The supramammillary
   nucleus: is it necessary for the mediation of hippocampal theta
   rhythm?. <I>Neuroscience</I>. <B>1995 Jul</B>;<I>67(2)</I>:301-12.
   <A NAME=r359></A></LI>
   
   <LI>O'Keefe J. Hippocampus, theta, and spatial memory
   &#91;Review&#93;. <I>Current Opinion in Neurobiology</I>. <B>1993
   Dec</B>;<I>3(6)</I>:917-24. <A NAME=r360></A></LI>
   
   <LI>Campbell IG, Feinberg I. Noncompetitive NMDA channel blockade
   during waking intensely stimulates NREM delta. <I>Journal of
   Pharmacology &amp; Experimental Therapeutics</I>. <B>1996
   Feb</B>;<I>276(2)</I>:737-42. <A NAME=r361></A></LI>
   
   <LI>Vallee J. Passport to Magonia (2nd ed). Contemporary Books.
   <B>1993</B> (Chicago) <A NAME=r362></A></LI>
   
   <LI>Perovic S, Pergande G, Ushijima H, et al. Flupirtine partially
   prevents neuronal injury induced by prion protein fragment and
   lead acetate. <I>Neurodegeneration</I>. <B>1995
   Dec</B>;<I>4(4)</I>:369-74. <A NAME=r363></A></LI>
   
   <LI>Blin O, Azulay JP, Desnuelle C, et al. A controlled one-year
   trial of dextromethorphan in amyotrophic lateral sclerosis.
   <I>Clinical Neuropharmacology</I>. <B>1996
   Apr</B>;<I>19(2)</I>:189-92. <A NAME=r364></A></LI>
   
   <LI>Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The
   serotonin syndrome associated with paroxetine, an over-the-counter
   cold remedy, and vascular disease. <I>Am-J-Emerg-Med</I>. <B>1994
   Nov</B>;<I>12(6)</I>:642-4. <A NAME=r365></A></LI>
   
   <LI>Fink M. Toxic serotonin syndrome or neuroleptic malignant
   syndrome?. <I>Pharmacopsychiatry</I>. <B>1996
   Jul</B>;<I>29(4)</I>:159-61. <A NAME=r366></A></LI>
   
   <LI>Bodner RA, Lynch T, Lewis L, Kahn-D. Serotonin syndrome.
   <I>Neurology</I>. <B>1995 Feb</B>;<I>45(2)</I>:219-23.
   <A NAME=r367></A></LI>
   
   <LI>Yoo Y, Chung H, Kim E, Kim M. Fatal zipeprol and
   dextromethorphan poisonings on Korea. <I>J Analytical Toxicol</I>.
   <B>1996 May-Jun</B>;<I>20(3)</I>:155-8. <A NAME=r368></A></LI>
   
   <LI>Suzuki T, Katto J, Saeki S, et al. Analgesic effect of
   dextromethorphan for postherpetic neuralgia &#91;Japanese&#93;.
   <I>Masui - Japanese Journal of Anesthesiology</I>. <B>1996
   May</B>;<I>45(5)</I>:629-33. <A NAME=r369></A></LI>
   
   <LI>Benade JG. A massive outbreak of food poisoning -- a reminder
   of the importance of proper toxic waste control. <I>South African
   Medical Journal</I>. <B>1996 May</B>;<I>86(5)</I>:551-2.
   <A NAME=r370></A></LI>
   
   <LI>Foreman J. <A HREF="http://www.critpath.org/newsletters/wtp/0196/shingles.htm">http://www.critpath.org/newsletters/wtp/0196/shingles.htm</A>
   <A NAME=r371></A></LI>
   
   <LI>Anderson P. <A HREF="http://www.emergency.com/philher2.htm">http://www.emergency.com/philher2.htm</A>
   <A NAME=r372></A></LI>
   
   <LI>Anonymous. Scopolamine poisoning among heroin users -- New
   York City, Newark, Philadelphia, and Baltimore, 1995 and 1996.
   <I>Morbidity &amp; Mortality Weekly Report</I>. <B>1996 Jun
   7</B>;<I>45(22)</I>:457-60. <A NAME=r373></A></LI>
   
   <LI>Kauppila T, Gronroos M, Pertovaara A. An attempt to attenuate
   experimental pain in humans by dextromethorphan, an NMDA receptor
   antagonist. <I>Pharmacology, Biochemistry &amp; Behavior</I>.
   <B>1995 Nov</B>;<I>52(3)</I>:641-4. <A NAME=r374></A></LI>
   
   <LI>Storrow AB, Magoon MR, Norton J. The dextromethorphan defense:
   dextromethorphan and the opioid screen. <I>Academic Emergency
   Medicine</I>. <B>1995 Sep</B>;<I>2(9)</I>:791-4.
   <A NAME=r375></A></LI>
   
   <LI>McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for
   the treatment of neuropathic pain: a double-blind randomised
   controlled crossover trial with integral n-of-1 design.
   <I>Pain</I>. <B>1994 Oct</B>;<I>59(1)</I>:127-33.
   <A NAME=r376></A></LI>
   
   <LI>Puchetti V, Faccini GB, Micciolo R, et al. Dextromethorphan
   test for evaluation of congenital predisposition to lung cancer.
   <I>Chest</I>. <B>1994 Feb</B>;<I>105(2)</I>:449-53.
   <A NAME=r377></A></LI>
   
   <LI>. <A HREF="http://atlas.comet.net/~bigfun">http://atlas.comet.net/~bigfun</A>
   <A NAME=r378></A></LI>
   
   <LI>Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase
   A inhibition in cigarette smokers. <I>Proc Natl Acad Sci USA</I>.
   <B>1996 Nov 26</B>;<I>93(24)</I>:14065-9. <A NAME=r379></A></LI>
   
   <LI>Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine
   oxidase B in the brains of smokers &#91;see comments&#93;.
   <I>Nature</I>. <B>1996 Feb 22</B>;<I>379(6567)</I>:733-6.</LI>
</OL>
</BODY>
</HTML>
